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ABSTRACT
This dissertation addresses the interface of genetics, genomics, and older adults
through a collection of three manuscripts that examine genetic and genomic testing and
decision-making across age groups. The dissertation offers evaluations of a new lens for
decision-making in genetics and genomics, a contextualization of the differences and
similarities of perceptions and beliefs that exist among age groups engaging in direct-toconsumer personal genetic testing (DTC PGT), an identification of two factors that
influence the decision to engage in DTC PGT, and an expansion of the current
applications of Protection Motivation Theory to include disclosure, finance, and advance
directive-management behaviors related to DTC PGT results.
Together these three manuscripts support and expand on previous understandings
about older adults and decision-making in genetics and genomics. The dissertation
findings identify many unique qualities of the 60+year old age group while also finding
similarities that span age groups. These findings support the need for further examination
of both age-group differences and the phenomenon of genetic or genomic decisionmaking. The differences and similarities among age groups will provide initial findings
on which future work in decision-making and decision-support can be built. The
dissertation’s focus on context as a key component of decision-making is both timely and
forward looking. The need to create unique and informed decision-support interventions
is growing as the personalized medicine movement begins to bring in more genetic
information. Consumer-driven healthcare demands consumer-sensitive approaches. The
use of behavioral economics and the Protection Motivation Theory as guides will help
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healthcare professionals to address the age-group differences and the individual contexts
that shape the genetic decision-making process.
Keywords: Behavioral Economics, Genetics, Older Adults, Protection Motivation
Theory.
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CHAPTER ONE:
INTRODUCTION
Exploring the Interface of Genetics, Genomics, and Older Adults
In the post-Human Genome Project era, as the cost of whole genome sequencing
is reaching the $1,000 mark, the need for complementary ethical, legal, social
implications (ELSI) research has increased (Green, Guyer, & National Human Genome
Research Institute, 2011). The intersection of technology, health care, and society is one
that is characterized by constant change; the possibility and promise of new approaches
to diagnosis, health promotion, and treatment and prevention of disease make genomics
an important part of improving healthcare. Ethical, legal, and social implications
research is imperative in supporting translational genomic science (Green et al., 2011).
The applications of genetic knowledge to clinical care have changed dramatically over
the past 25 years and are anticipated to change even more as genetic technology,
knowledge, and access increase in the future (Catenacci et al., 2015; Green et al., 2011;
Sobel & Cowan, 2000a). These changes in applications are happening, not only because
of the increase in the relative availability of testing, but also because of the growing
understanding that genetic diseases are family diseases (Forrest et al., 2007; Sorenson,
Jennings-Grant, & Newman, 2003).
Published studies addressing families and genetics cover a range of topics
including risk perceptions, disclosure of results, and effects of results on family (Forrest
et al., 2007; Lautenbach, Christensen, Sparks, & Green, 2013; Sorenson et al., 2003). As
an effect of the growing number of older adults who are living longer and engaging with
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newer healthcare technologies, the family unit, as it has been characterized in the past, is
in flux (Bookman & Kimbrel, 2011; Seals, Justice, & LaRoca, 2015). It is important to
have a general understanding of the familial and generational impacts that genetic testing
decisions can have through the avoidance or revelation of new genetic information about
a person and his family (Frazier & Ostwald, 2002).
The understanding of older adults’ genetic knowledge, genetic perceptions, and
beliefs is limited. The few studies that address aspects of older adults in relation to
genetics tend to highlight low levels of genetic literacy and knowledge among older
adults and often associate it with lack of exposure to the knowledge in their education
(Ashida et al., 2011; Carere et al., 2015; Frazier, Calvin, Mudd, & Cohen, 2006; Morren,
Riken, Baanders, & Bensing, 2007; Ostergren et al., 2015; Skirton, Frazier, Calvin, &
Cohen, 2005). Other findings regarding older adults and genetics include an increased
likelihood to defer to clinical expertise of a health care provider rather than to take
responsibility for the issues related to medical genetic decisions (Frazier et al., 2006) and
an altruistic and generative quality when considering the possibility of genetic testing
(Skirton et al., 2005). While genetic knowledge may be foundational to many other
tasks related to genetic testing, there are many other factors and influences that must be
considered with the complex undertaking of making decisions regarding genetic
information.
This dissertation is intended to increase current understanding of the perceptions,
beliefs, attitudes and behaviors of older adults regarding genetic and genomic testing and
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decision-making, as well as, the usefulness and application of genetic and genomic
information.
Problem Statement
While it long has been understood that any genetic or genomic testing can have
implications for more than one person (e.g. the information gained from BRCA testing in
an older adult female with breast cancer, which may affect her three daughters), there is
limited understanding of how genetic decision-making among older adults is undertaken,
and how different parties may be engaged in the decision-making processes. Recent
academic and practice-based discussions about incidental findings demonstrate the need
for ethical and policy-focused studies of advancing medical technologies. The inclusion
of new technologies in healthcare requires finding a delicate balance between doing too
little, too late and too much, too early.
As a result of the progression of genomic science and the increasing length of life
of older adults, it is imperative that research focuses on the implications that genomicrelated decision-making and testing have on older adults and their families. Research
must address the needs of older adult patients and their adult children (families) as they
engage in making genetic testing-related decisions (Sobel & Cowan, 2000a). In order to
begin to better understand the implications of genetic information on older adult patients
and their families, further descriptive study is required.
The knowledge made possible through early descriptive studies is integral to the
development of future tools and identification of best practices. Much work in genomics
continues to focus on the younger populations (e.g. incidental findings disclosure, adult-
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onset disease risk disclosure during childhood, parental consent), but very little attention
has been paid to older adult populations and the potential effects that genomics may have
on their lives and consequently the lives of their family members. With the rapid growth
of the older adult population and increased involvement of family in the care of older
adults, discussions regarding genomics have the potential to affect the older adult-family
relationship in ways that are unforeseen in younger populations.
Statement of Significance
This dissertation will provide important knowledge about older adult patients and
their perspectives about genomics and genetics as compared with younger age groups.
The areas of exploration that are key to this study include: the framing of genomic and
genetic decision-making; the examination of age group differences in genetic knowledge,
perceptions, and beliefs; the exploration of factors that influence decision-making to
engage in genetic testing among age groups; and the evaluation of a model for the
prediction of direct-to-consumer personal genomic testing (DTC PGT) results utilization
behaviors regarding insurance, finances, retirement, advance plans, and disclosure to
another person.
Understanding the differences and similarities of decision-making practices
among adults of various ages when engaging in personal genetic or genomic testing as
well as examining their general perceptions, beliefs, and attitudes about genomics will
provide a valuable foundation on which scientists and clinicians can build tools to aid
decision-making regarding genetic testing. Additionally, this work has the potential to
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lead to future policy and practice changes to ensure that older adults’ needs and best
interests are met and supported.
Theoretical Framework
The guiding theoretical framework for this dissertation is the Protection
Motivation Theory (PMT) as described by Rogers (Maddux & Rogers, 1983; Rogers,
1975, 1983). Originally designed based on the expectancy-value theory with a focus on
describing the relationships between fear appeals and health behaviors, the PMT is an
intrapersonal-type theory that supposes that individuals’ abilities to take in, react to, cope
with, and manage threats or negative outcomes are related to their appraisals of the threat
and their appraisal of their own coping abilities for dealing with the threat (Floyd,
Prentice-Dunn, & Rogers, 2000; Rogers, 1983). Scientific applications of the PMT have
varied since its introduction (Floyd et al., 2000). The application of the PMT has
included political and environmental concerns in addition to preventative health
behaviors, screening behaviors, and disease and injury prevention behaviors.
Protection Motivation Theory Concepts and Relationships
The PMT (Maddux & Rogers, 1983; Rogers, 1983), in its revised version,
features three main concepts: threat appraisal, coping appraisal, and protection motivation
(Norman, Boer, & Seydel, 2005). The concepts of threat appraisal and coping appraisal
are better described in the revision of the theory with expansion of the cognitive
mediating processes that are integral in contributing to related intentions and attitudes
through the addition of the self-efficacy concept (Floyd et al., 2000; Maddox & Rogers,
1983; Rogers, 1983).
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Threat appraisal is best described as the combination of the perceived severity and
the perceived vulnerability related to the negative outcome of concern (Rogers, 1983).
This negative outcome could be a disease diagnosis, injury, or some other negative
experience that can be avoided. Perceived severity is defined in terms of a person’s
beliefs about the potential bodily harm, interpersonal threats, and intrapersonal threats
that would result from the negative outcome. Perceived vulnerability is defined in terms
of a person’s beliefs that they may experience the negative outcome.
Coping appraisal is described as the combination of perceived self-efficacy and
response efficacy related to the negative outcome of concern (Maddox & Rogers, 1983;
Rogers, 1983). Response efficacy is defined as a person’s beliefs related to the
effectiveness of coping responses. Self-efficacy is defined as a person’s beliefs about
their ability to perform or not perform a behavior (e.g., a recommended response to the
negative outcome of concern). The addition of the concept of self-efficacy is the major
difference between the initial introduction of the PMT and the revision (Rogers, 1983).
Protection motivation is best described as the intent to adopt a recommended
course of action or engage in a protective behavior to limit the likelihood of experiencing
the negative outcome (Maddux & Rogers, 1983; Rogers, 1975, 1983). The PMT is based
on the assumption that there is a positive linear relationship among severity of the threat,
vulnerability to the threat, the ability to cope with the threat, and that engaging in the
behavior of concern will decrease risks of the negative outcome (Rogers, 1983). The
PMT is key in this dissertation work in that it provides a framework for understanding the
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perceptions that older adults have about genomics, and can offer some insight into their
individual realities when it comes to managing genomic information.
Purpose
In addition to the theoretical framework, the dissertation is guided by three
primary aims and one exploratory aim:
Primary Aim 1: Evaluation of behavioral economic concepts as a suitable lens for
framing decision-making in genetic and genomic testing.
Research Question 1: What behavioral economic concepts fit genetic and
genomic decision-making situations?
Primary Aim 2: Characterize the perceptions and attitudes of older adults regarding
genetics, genetic testing, and genetic information.
Research Question 2: What are older adults’ perceptions regarding genetic
testing and genetic information?
Primary Aim 3: Describe the differences in behaviors of genetic testing decision-making
and application of genetic information among younger and older age groups.
Research Question 3: What are the decision-making processes used by older
adults when making decisions regarding genetic testing and genetic information?
Exploratory Aim: Explore the application of the Protection Motivation Theory to genetic
information disclosure and utilization behaviors among age groups.
Research Question 4: What is the relationship among threat appraisal, coping
appraisal, disclosure of genetic results, changes in healthcare insurance and
advanced planning behaviors?
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This dissertation contextualizes decision-making in genetics and genomics with a
specific focus on older adults in comparison to the other age groups. These research
questions are answered through three manuscripts: the first manuscript explores genetic
and genomic decision-making through the lens of behavioral economics; the second
manuscript identifies and explores differences in age groups regarding influences on their
decision to seek personal genomic testing; and, the third manuscript explores the use of
the PMT to predict disclosure, insurance, retirement, and advanced planning behaviors
among Impact of Personal Genomics (PGen) participants following receipt of their
personalized genomic testing results.
This dissertation seeks to further the understanding of the nature of differences
among age groups regarding genetic knowledge and perceptions, and add an exploration
of decision-making, perceived genetic utility, and the influencing factors on the actions
taken as a result of receiving genetic testing results (e.g. disclosure, adding insurance
coverage, etc.). The three manuscripts in this dissertation seek to frame the interface of
genetics, genomics and older adults. The first manuscript focuses on behavioral
economics as a lens for understanding decision-making related to genomics. The second
manuscript is based on an analysis of the PGen study data examining commonalities and
differences in the PGen study populations’ genomic perceptions and knowledge and the
influencing factors that are related to choosing to engage in genomic testing as they differ
among three age groups (19-39, 40-59, and 60+). The third manuscript explores age and
PMT as a suitable model for predicting or explaining behaviors related to the use of
genomic information provided in DTC PGT results. These three manuscripts together
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advance the understanding of decision-making in genetics and genomics across age
groups.
Methodology
The three manuscripts chosen for this dissertation are combined to expand current
understanding of the perceptions, beliefs, attitudes and behaviors of older adults
regarding genomics, genomic testing, genomic decision-making, and the usefulness and
application of genetic information. Exploration and explanation of relationships among
beliefs and behaviors within and among age groups with regard to genetic information
will increase the knowledge base needed to better guide decision-making in personal and
clinical settings.
The first manuscript (Chapter 2) entitled “Behavioral Economics: A Lens for
Understanding Genetic and Genomic Decision-Making,” is a review article that
introduces three behavioral economic concepts and couples them with appropriate genetic
and genomic decision-making examples in an evaluation of fit between genetic/genomic
decision-making and behavioral economics. In addition to the general overview of
behavioral economics and the three featured concepts, the manuscript also identifies next
steps in helping to frame genomic decision-making using behavioral economics.
The second manuscript (Chapter 3) entitled “Personal Genomic Testing:
Understanding Age-Group Differences in Genetic Knowledge, Perceptions, and
Decision-Making” is a data-based article using the PGen Dataset that examines
differences among age groups related to perceptions of genomics, genomic knowledge,
and influences on decision-making related to engaging in genomic testing. This is
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accomplished through two statistical analysis approaches. First is a comparison of the
changes between baseline and six-month measures among the three age groups’ genetic
knowledge, response efficacy, and self-rated competency in genetics. An analysis of
variance (ANOVA) was used to conduct these analyses. Also, ANOVA was conducted to
evaluate the changes among the three age groups’ personal utility measures from the 2-3
week and the six-month follow up surveys.
Second, items evaluating ratings of importance for reasons for testing and amount
of consideration given to decision factors were evaluated first by using factor analysis to
identify common loading of the factors and then mean scores for each of the two factors
were compared among the age groups using ANOVA of means.
The third manuscript (Chapter 4) entitled “Using Age and Protection Motivation
Theory to Explore Personal Genomic Testing Result Utilization” is also a data based
article from the PGen dataset. This article focuses on evaluating the PMT as a model for
examining the use of genomic testing results looking at similarities and differences
among age groups. This analysis consists of contingency tables examining age group
membership and the following PMT concept measures: perceived utility of genetic
information, genetic knowledge, perceived severity of genetic results, perceived
vulnerability to genetic illness after getting results, response efficacy after results, and
self-efficacy after getting results on whether or not a participant chose to discuss genetic
results, make a change in their healthcare insurance, make a change in their retirement, or
make a change in their advanced planning behaviors.
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The final chapter (Chapter 5) brings the three manuscripts together and attempts
to contextualize the dissertation findings. The three manuscripts work to frame the issues
related to decision-making in genetic and genomic testing among older adults.
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CHAPTER TWO:
BEHAVIORAL ECONOMICS: A NEW LENS FOR UNDERSTANDING GENOMIC
DECISION-MAKING
Abstract
Behavioral economics has been identified in previous articles as a key component of
understanding genomics. This article seeks to take the next step in examining the insights
that can be derived from using them in combination. As genomic science continues to
permeate clinical practice, behavioral economics will continue to warrant further
exploration and education for nurses and health care providers. Decisions associated with
genomics are often not either/or in nature but are complex and may be challenging for all
involved. These complexities make behavioral economics an interesting option for
framing our understanding of these decisions. This article offers a brief introduction to
behavioral economics as a possible tool to help with decision-making related to
genomics. Behavioral economic concepts that are specifically examined as new ways to
view the complexities of genomic decision-making include relativity, deliberation, and
choice architecture. Each concept is discussed with explanatory examples to help
understand applicability to clinical practice. The article also explores the next steps and
practice implications for further development of the behavioral economic lens.
Keywords: behavioral economics, genomics, decision-making, nursing
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Behavioral Economics: A New Lens for Understanding Genomic Decision-Making
Introduction
As genomics advances with the development of additional screening and testing
procedures, it is imperative to understand how the expanding capacities of genomic
science can be integrated into practice. Further, as translational science comes to the
forefront in genomics, scientists and clinicians alike must assess the social, ethical, and
familial implications of the increased power and availability of genomic testing. Over the
course of the last 20 years, access to the genome has increased in numerous ways. As a
result we have more information available to us than ever. These changes require diligent
work in research and scholarship to ensure that the very best applications are safe and
equitably available for those affected (Green, Guyer, & National Human Genome
Research Institute, 2011).
The field of behavioral economics, the study of forces and principles behind the
decision-making behaviors of humans, is growing rapidly (Madden, 2000). The field is
highly focused on economic contexts; however, applications outside of a strictly
economic environment are promising. Many opportunities for the application of
behavioral economics have been aligned with incentivized health outcomes and health
behavior changes (Bickel & Vuchinich, 2000; Hostetter & Klein, 2013; Hough, 2013).
These concepts may also prove very useful in helping clinicians better understand
decision-making of patients in various settings and situations. In the realm of genomic
decision-making there are several opportunities for the application of behavioral
economics in clinical practice that bear exploration. Although recent articles have
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discussed behavioral economics and genomics, they have not fully explored the
mechanisms related to genomic decision-making (Blumenthal-Barby, McGuire, & Ubel,
2014; Blumenthal-Barby, McGuire, Green, & Ubel, 2015).
It is in the setting of the patient-provider relationship where behavioral economics
can be valuable. Understanding the relationship as a continuum ranging from laissez faire
to authoritarian approaches, behavioral economics, when applied to decision-making, can
help to balance these approaches (Bayles, 2010). Each participant enters into the patientprovider relationship with an information asymmetry-the health care provider brings the
expertise and the knowledge of the clinical situation while the patient brings an
abundance of knowledge about themselves, their desires, their experiences, and their
lives. Behavioral economics can help to navigate the middle-ground balancing the
knowledge of the provider with the needs of the decision maker (Hough, 2013).
Behavioral economic approaches can open the door to conversation, which will allow for
the identification and elimination of the information asymmetry that often exists in
genomic decision-making encounters. This article aims, first, to introduce nurses and
other health professionals to key behavioral economic concepts, providing genomicsbased examples, and then to explore next steps and practice implications for behavioral
economics and genomic decision-making for nursing and healthcare.
Genomic Decision-Making in a Behavioral Economic Context
Several key framing concepts from behavioral economics are important for a
better understanding of the unique and often complex case of genomic decision-making.
Chiefly, it is important to understand the concepts of relativity, deliberation, and choice
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architecture to adequately contextualize genetic testing decisions within behavioral
economics.
Relativity
Relativity, a central part of the human decision-making construct, allows for
understanding the relative advantages of one option compared to others (Ariely, 2009). In
exploring this concept it is important to note that the comparison must be among similar
and available alternatives. Genomic testing may offer similar alternatives; for example,
providers and patients can choose among different panels of genetic tests offering a range
of levels of information including testing for additional (often related) genomic
variations. This choice could be limited by insurance coverage and financial constraints,
but sometimes a similar choice is available. However, genetic testing often has no
alternative for relative comparison, and thus there is no comparable methodology that
offers the opportunity to find out the same level of information.
The initial question for those facing decisions about genomic testing is whether to
test at all. Absent alternatives, the decision is between knowing or not knowing genomiclevel information and the possibility of that genomic information changing the course of
care. In applying relativity to these situations there is an increase in the amount of
information that is needed, specifically regarding the type, amount, and nature of the
information provided by the test results and how the results may influence next steps in
patient care.
There are situations where there are much more affordable and clinically
expedient choices that can be made. One example is testing serum cholesterol levels
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rather than doing genetic testing related to familial hypercholesterolemia (FH). Current
guidelines do not recommend genetic screening evaluation of patients for FH due largely
to cost (Robinson, 2013). Since there are, currently, no gene-specific treatments related
to treatment of FH, knowing the specific genotype has limited value, so treatment with
lifestyle, statins, and close clinical monitoring is still recommended, regardless of
genetics.
Another example is the use of regular colonoscopies rather than screening for
familial polyposis-related genes. A finding in a colonoscopy may itself lead to further
testing, but the presence of several polyps does not establish a diagnosis of familial
polyposis. Those patients who are given results from testing of polyposis-related genes
might be able to better inform their practice of colonoscopy screenings. Those with
genetically confirmed increased risks for familial polyposis would be best served not by
general screening guidelines regarding regular use of colonoscopies, but by the use of a
more frequent screening beginning at an earlier age (Syngal et al., 2015).
These two examples highlight how, in terms of relativity, comparison is very
important in making genomic testing-related decisions. Currently, the genomic testing
information has limited influence on the course of treatment for FH; however, with the
familial polyposis there is a great difference in the screening trajectory for a patient with
a confirmed increased genetic risk for polyposis.
A related concept of importance is anchoring, the strong behavioral influence
produced by first impressions (Ariely, 2009). While often applied in an economic
context, where first prices are found to influence willingness to spend a certain amount of
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money on an item, the concept of anchoring can also be applied to health care decisionmaking. If a patient or a family member has had a positive experience with genomic
testing, then it might encourage them to engage in genetic testing. If they have had a
negative experience, then the opposite influence may be observed.
Deliberation
Deliberation, the effort by an individual to identify new alternatives, new rules,
for solving a problem, becomes important when practical problem solving guidelines or
heuristics-based decision tactics have failed in enabling patients or families to make
decisions regarding new dilemmas (Montzavinos, 2001). Identifying prior knowledge
and available evidence and applying that information when facing new problems is
central to the idea of heuristic decision-making. However, as with relativity, decisions
are taken in context. As the mind seeks these new alternatives, there is opportunity to
address a problem through “ready-made solutions” or to apply the anecdotal knowledge
of those who have encountered the same or similar situations in the past (Montzavinos,
2001, p. 39). This alternative is viable for decision-making in genetic testing, but it is
also important to realize that, as with any application of the ready-made solution, the
context of the individual making the decision may be different from that of the person
providing the experience supporting the ready-made solution. When heuristics are
inapplicable or have failed, Montzavinos asserts, the individual resorts to a deliberative
approach.
The situation that one person faces in a diagnosis and testing decision is likely to
differ, subtly or grossly, from the anecdotal solution. Contextually, genomic decisions are
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rarely identical from patient to patient, even within families. Even though test panels and
results may be the same for several people, their lives and familial, environmental,
emotional, and financial contexts vary making the application of ready-made solutions
difficult or impossible (Sweeny, Ghane, Legg, Huynh, & Andrews, 2014).
It seems relatively clear that there is limited potential for identifying a simple
ready-made solution for decision-making in genomics. In this regard, behavioral
economics may, when applied to the general situation of making decisions regarding
genomic testing, prove valuable in helping patients to make the best, most informed
decision, one that best aids patients. The way to best shape these processes must rely
heavily on choice architecture and requires a clear understanding of several of the
dynamics at play (Thaler & Sunstein, 2008).
Choice architecture
Choice architecture is the art of shaping decisions by supporting pre-existing
human tendencies through designing choices within a framework that will encourage a
certain choice. It is one mechanism that can be explored in attempting to best assist
patients and families as they engage in genetic decision-making. There is a clear
difference between choice architecture and ‘manipulation’ in that choice architecture
merely provides guidance for decision-making without attempting to limit a person’s
autonomy (Sunstein, 2015). Choice architecture can address some of the external and
internal contexts of decision-making with regard to genetic decisions. Thaler and
Sunstein (2008) offer some insight on choice architecture that, when applied to genomics,
further supports the unique nature of the decisions to be made.
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The application of choice architecture is very well suited to encouraging patient
choices regarding wellness and preventive health. In such situations, choice architects
employ “nudges” to frame decisions about the most appropriate route as the easiest one
without limiting options. There are numerous ways to nudge decision-makers, and often
the processes are subtle because of their reliance on probable human behaviors; context is
key. The scope and level of information involved in decision-making in genomics
requires further exploration when contemplating nudges and choice architecture.
Understanding the unique nature of genomic information will help sharpen nudge
methods but also improve our understanding of their applicability in aiding patient and
family member decisions – and the ethical implications of employing such methods. Key
nudge tactics that warrant further exploration in the setting of genomic testing decisions
include: default choices and mapping (Thaler & Sunstein, 2008).
Default choices. When no action is taken by the patient in genomic decisionmaking, some default choice results. This can be a slippery slope. Because the impact
of genetics can extend beyond the decision maker or patient, it is imperative that any
default choice be respectful and protective of all parties potentially affected by the
choice. If choice architects were to use “nudges” in genetics decision-making to prompt
a default choice, then perhaps the safest default would be the null, no testing, choice, one
with the potential to affect the fewest people and not to impose effects on others,
inadvertently or not. There are some examples where the default to test, such as the use
of the newborn screening apparatus to test for a panel of specific genetic variants that can
lead to disease, is established in law (National Human Genome Research Institute, 2015).
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In this case, the default is set up to ensure early identification and intervention in patients
with the selected genetic variants to ensure quality of life. Some of the selected variants
have potential implications for other people beyond the patient (e.g., the tested child’s
parents and other family members). The policy is designed to protect the perceived best
interests of the child in order to affect change through early identification, early initiation
of treatment, and improvement of clinical outcomes. In other situations, a testing default
choice is not a logical standard; it would be a nudge that discourages exploring other
options when faced with a new testing, not ready made, testing decision. At this time,
because the implications of genetic testing results with regard to patient and family life
are unclear when testing in older populations, there is no clear path to a default choice for
later life genetics testing.
Mapping. Mapping can be used as a way to nudge patients when making
decisions regarding genetic testing. Mapping draws on a person’s knowledge and
experiences to establish, by analogy to prior decision situations, a pathway to a decision
in previously unexplored territory. However, as with most attempts to help shape a
decision, there are some drawbacks. Not all genetic testing may lend itself directly to
mapping, so it is important to be aware of the variables that may limit the ability to map
out a decision pathway. These variables, fairly consistent in genomic decision-making,
include the context and timing of the decision, healthcare provider biases toward one type
of testing or toward not testing at all, information asymmetry creating an increased
patient dependence on providers for appropriate information, and the social-emotional,
and financial “costs” of genetic testing. Those patients and families considering genetic
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testing may need more time to make decisions, increased knowledge sharing between
providers and patients and families to limit information asymmetry, and an opportunity
for deeper exploration of implications with patients to ensure that post-testing effects on
patient and family lives are at least acknowledged if not mitigated in some way.
The BreastCARE intervention studies (Kaplan et al, 2014; Livuadais-Toman et al,
2015) provide an excellent example of how mapping might be helpful with genomics.
BreastCARE sought to increase awareness and communication among patients and
providers by using appropriate and validated measures of risk for breast cancer to
structure a risk-assessment intervention. This strategy helped to increase communication
of breast cancer-related information without increasing concern among patients. This
intervention did not lead to a genomic testing decision per se, but it used existing
knowledge to help shape the decision to speak with a provider about breast cancer. Those
who undergo this intervention may, in turn need, to be assisted in making the decision to
seek testing for the genes associated with breast cancer, and this too could be mapped
using a similar intervention.
Next Steps for Behavioral Economics and Genomic Decision-Making
As genomic testing becomes more main stream and as more people are faced with
making decisions about testing and results, it will bring new challenges to old procedures
and policies. Studies of decision-making processes and concerns and of ways to facilitate
decisions about testing that account for the various stakes of patients and families will be
crucial in adapting existing processes and developing new approaches. Examining
genetic decision-making through a behavioral economic lens allows for the exploration of
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the nuanced factors in play for patients and their families in this rapidly emerging field.
Work must be begun to characterize the decision-making processes undertaken by
patients, family caregivers, and their healthcare providers in an effort to provide context
for future studies of behavioral economic approaches in facilitating and shaping the
decision-making process. While the personal and varied nature of genetic information
makes restrictive and finely detailed descriptions of processes used in genomic decisionmaking less likely, there is a need to have a clearer understanding of any processes that
are undertaken.
Incorporation of the elements of behavioral economics can also help to create a
positive decision-making environment for those who are faced with these often difficult
genetic testing decisions. As explored here, genomic testing is unique among medical
tests because of the nature of the information and the current lack of alternatives available
to get the same information. This unique nature makes the application of behavioral
economics and choice architecture techniques to be of some value, but studies identifying
ways to better support decision-making are imperative. Understanding if there is a
decision pathway or some other tool that could be used to help patients consider the
multiple variables of genomic testing is key for future steps in supporting patient
decision-making.
An appreciation of the mechanisms involved in behavioral economics can assure
that deciders are not forced into particular choices by the contextual forces that can
disproportionately influence important decisions resulting in a choice that may not fully
reflect a patient’s values or represent a full deliberation of the situation. Behavioral
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economics does not rest solely on the belief that humans will always act rationally in a
given situation, but rather accounts for contextual influencers such as emotions, cognitive
biases, and other internal and external pressures (Ariely, 2009). There must, therefore, be
a better understanding influence of the social, emotional, and financial costs has on
medical decision-making, and more specifically genomic decision-making. There is a
wide range of variables that each person will uniquely encounter, but there are also many
commonalities that must be accounted for and further explored (Lerner, Li, Valdesolo, &
Kassam, 2015). One behavioral economic concept that has been noted is the presentcenteredness, termed “present bias,” that shapes decision-making (Hostetter & Klein,
2013). Awareness of present bias is important in understanding how costs are perceived
when making decisions. Understanding the value of information at the moment of testing
and understanding the possible implications for future decisions of the patient and the
patient’s family is imperative in assisting with decision-making.
It is important to consider how behavioral economic concepts can be applied in
clinical practice. In the current patient-centered care environment, nursing has a unique
role in patients’ decision-making processes. Relationships with patients and their
families in times of illness and wellness place nurses in the context of making important
decisions. Often nurses are seen as a source of information and clarification when
communication with physicians or specialists is limited. Nurses and other healthcare
professionals must seek to better understand the context of the care that they are
delivering to their patients. The behavioral economic concepts described in this article
offer a good start for better understanding decision-making, specifically in a genomic
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context. Beyond the genomic focus of this article, nurses can benefit from further
exploring these concepts, understanding how their own practices may inadvertently
influence patient and family decisions, and incorporating some of these approaches in
supporting patients and families as they make difficult decisions.
While these behavioral economic concepts do bring a new lens to the work that
must be done regarding genetic decision-making, they do not replace the key concepts
that are embodied in high quality health care provision. It is important to keep these
professional and ethical standards in mind as decision-making work is undertaken.
Patients are more than the sum of their complaints, diseases, or syndromes, and the
process of diagnosis and treatment of illness is complex and multifaceted, possibly even
more so when genomics are involved (Gorovitz, 2010). The use of the behavioral
economic mechanisms to support patient decision-making is helpful in managing the
complexities of these decisions through the use of information and expertise while still
respecting autonomy of patients and families. This is the essence of the marriage of
behavioral economics with the patient-provider relationship—the use of these approaches
to overcome the asymmetry of information that often exists through thoughtful and
deliberate support of patient decision-making.
Continued interdisciplinary, collaborative exploration of decision-making is an
important part of assuring that patient decision-making with regard to genomics is
supported to the highest possible level. Understanding the core concepts of behavioral
economics and choice architecture is key in this endeavor, and the use of these concepts
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to inform future studies will allow for improvement of the patient experience in genomic
decision-making.
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CHAPTER THREE:
PERSONAL GENOMIC TESTING: UNDERSTANDING AGE GROUP
DIFFERENCES IN GENETIC KNOWLEDGE, PERCEPTIONS, AND DECISIONMAKING
Abstract
Purpose of The Study: This study describes differences among three age groups (19-39,
40-59, 60+ years old) who are new customers of direct-to-consumer personal genomic
testing (DTC PGT) in their knowledge and perceptions of genetics as well as factors that
influence their decisions to test.
Design and Methods: This analysis of the Impact of Personal Genomics Study used a
sample of 887 study participants who were surveyed three times via online survey
(baseline [before receiving results], 2-3 weeks after receiving results, and 6 months after
receiving results). ANOVA was used to evaluate change in means of Genetic
Knowledge, Self-Rated Genetic Competency, Personal Genetic Utility, and Genetic
Response Efficacy over time and also across the three age groups. Factor analysis was
used to identify factors related to the decision to engage in DTC PGT.
Results: For Genetics Knowledge and Personal Genetic Utility scores, the 60+ year old
group had significantly lower scores when compared with the other two age groups.
Factor analysis identified two strongly loading factors with themes of ‘Health and Future’
and ‘Curiosity and Intrigue’ oriented items. There was a significantly lower mean ‘health
and future’ score among the older adult population.
Implications: While the sample for this study was drawn from DTC PGT customers,
these results support previous understandings that older adults have different views of
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genetic and genomic testing than the younger age groups. Differences among the age
groups support the need for further study and evaluation of approaches to meet the unique
needs of older adults when it comes to genomic testing and understanding the value and
use of genomic results. As the aging population grows and their care is guided by
genomic testing, these areas of age group differences may hold a place in helping to
design interventions to support and engage older adults in their precision care.
Keywords: decision factors, genetic testing, genetic knowledge, older adults
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Personal Genomic Testing: Understanding Age Group Differences in Genetic
Knowledge, Perceptions, and Decision-Making
Introduction
The drive to make healthcare a personalized, precision science means that
individual complexities will be very influential in tailoring interventions. Genomics and
genetics are part of the science that will shape the personalization of medical care. As
work in health sciences moves closer to precision medicine, the personal context in which
healthcare encounters occur is becoming more important (Bayliss et al, 2014).
Understanding the contextual factors and influencers of patient decision-making
behaviors is an important part of understanding personal contexts and is key in helping to
support patient decision-making. While underlying genetic knowledge is important, the
existence of other contextual factors such as perception of genetics, response efficacy,
and genetic utility may also offer some important insight into decision-making. The
purpose of this study is to explore differences among three age groups in genetic
knowledge, perceptions, and decision-making influencers.
There has been limited study specifically about the knowledge and perceptions of
older adults related to genetics and genomics. Among those few studies, older adults have
demonstrated a willingness to participate in genetic testing if it demonstrates value and
has promise for illness prevention or benefit for future generations (Skirton et al., 2005).
Older adults also identified the importance of family involvement and clarity of testing
purpose (Frazier et al., 2006). Several quantitative studies have reported some agerelated differences with regard to knowledge and beliefs. Older adults have been found to
have lower genetic knowledge scores when compared with other age groups (Ashida et
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al., 2011; Carere et al., 2015; Morren et al., 2007). Additionally, some differences in
beliefs about genetic causes of weight and obesity have been associated with differences
in age (Ashida et al.). A significantly lower comprehension of genetic results has been
noted among older adults when compared with younger adult groups (Ostergren et al.,
2015).
Genetic Decision-Making
An understanding of how decisions are made regarding genetic testing can help
health care providers and genetic counselors improve their facilitation of patient and
family decision-making. In the early years of prenatal diagnosis and pre-conception
genetics, clinical professionals and medical ethicists identified the need to support
individualized decision-making related to genetics (Pauker, 2013; Paulsen et al., 2013).
The research-based descriptions of decision-making of patients with regard to predictive
genetics addressed ideas and questions, such as: How has a treatment option been
developed? Is treatment curative or palliative in nature? If treatment is unavailable, does
testing offer some opportunity to decrease ambiguity? Does genetic information impact
reproduction decisions? Could genetic information assist other family members?
(Henderson, Maguire, Gray, & Morrison, 2006; Katz, Kurian, Morrow, 2015; Paulsen et
al.).
The study of decision-making is very common in gene-linked cancer diagnosis
and treatment (Iredale et al., 2008; McQuirter et al., 2010; Sames, 2008). The
understanding of gene significance in hereditary breast cancer has brought increased
focus on decision-making and decision aids for patients with BRCA1 and BRCA2
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mutation-linked familial breast cancer. In Iredale, et al.’s study, the complexity of
decision-making and familial breast cancer changes as the level of risk changes for the
patient. A common element, however, was a desire for discussions of preventive and
lifestyle related information that does not offer false hope (Iredale, et al., 2008). The
desires of the participants (breast cancer patients) for specific types of information were
also different when compared among risk-groups. The participants were sensitive to their
own concerns and also the perceived preferences of healthcare professionals when
choosing among treatments. While these tests are more targeted, education about risks
and limitations regarding genetic analysis of the whole genome helps to decrease
uncertainty and decisional conflict (Sanderson et al., 2013).
Familial linkage and the witnessed experiences of their relatives’ having cancer
are driving factors for making the decision to seek out prophylactic mastectomy as a
method of seeking control among people at risk for breast cancer (McQuirter et al.,
2010). The process is unique to each woman, because of her previous experiences and
her life situation at the time of making the decision (McQuirter et al.). Multiple concerns
influence patient decisions, including previous personal or familial experiences with
cancer; and the desire to have some control over decisions, personal image, provider
recommendation, and support. While some of these concerns are truly specific to
mastectomy decisions, many can be generalized to the population of patients with
BRCA1 and BRCA2 mutations at the very least. Focusing on a treatment decision in
response to genetic findings, McQuirter and colleagues offer insight into the same areas
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of concern (e.g., the value of testing; influence on family members) other patients
contemplating genetic testing or facing unfavorable genetic results may encounter.
While there has been a strong history of paternalistic directives by health care
professionals in genetic decision-making, there is an increased involvement of patients in
decisions related to genetic testing. In the study of cancer, specifically breast cancer
diagnoses, there is an increased reliance on patient preferences (Katz et al., 2015). One
important aspect of increased patient involvement is ensuring that patients are aware and
accepting of the extended implications of the genetic information on patients’ relatives
and possibly future cancer diagnoses. This increased involvement of patients is also
associated with an increased use of genetic technologies in patient care across multiple
cancers, not just limited to breast cancer.
Decision-Making Among Older Adults
Gerontologists and geriatricians encourage preservation of autonomy and control
in older adult patients (Mallers, Claver, & Lares, 2014). When older patients are
supported in maintaining control over decisions, they are more successful through the
aging process and have better outcomes (Mallers et al.). The study of decision-making in
older adults is emerging on the health care forefront. In light of the importance of
autonomy to older patients, an emphasis to better understand the value older adults place
on shared decision-making in the health care setting is needed. The underpinning
concepts of shared decision-making (e.g., information exchange, deliberation regarding
preferences, and developing agreement between patient and provider) were very similar
to the desires that the older adults had for their interactions with providers (Burton et al.,
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2015; Naik et al., 2005). The level of information sought varies by patient; however, most
favor the provision of limited amounts of information (Burton et al.). Deliberative
capacities have been found to be lower among older adults than younger adults when
dealing with new information; however older adults demonstrated a preservation of
affective abilities when dealing with experience based decision-making (Huang, Wood,
Berger, & Hanoch, 2015).
In summary, the current understanding of genomic decision-making among older
adults is limited. The differences among the age groups that have been identified are in
genetic knowledge and perceptions of gene-obesity linkages. Genetic testing decisionmaking has, in general, been found to be associated with the level of information and
provider perspective, but there are limited studies of the older adult populations with
regard to genetic decision-making. In general, it is important for older adults to be
involved in their own decision-making; however, older adults may need more support
when they engage in information processing and decision-making related to costs and
benefits and are presented with information about a new or unfamiliar decisional
situation.
While genetic knowledge has been shown to differ among age groups, the other
contextual factors and motives that influence decision-making may also differ among age
groups. There are no studies that explore those differences across the age groups. In this
study we sought to investigate these age differences by answering two questions through
secondary analysis of the Impact of Personal Genomics (PGen) data: 1) What are older
adults’ perceptions regarding genetic testing and genetic information as compared to
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other age groups? 2) What influences decision-making of older adults when deciding to
engage in direct-to-consumer personal genomic testing (DTC PGT) as compared to other
age groups?
Design and Methods
The PGen study was approved by the Partners Human Research Committee and
the University of Michigan School of Public Health Institutional Review Board. Each
participant completed an electronic informed consent prior to being enrolled. Details of
design and data collection for the PGen study have been reported previously (Carere et
al., 2014; Lehmann et al., 2012).
The sample was recruited between March and July 2012 from new customers of
23andMe and Pathway Genomics, two independent DTC PGT agencies, after they placed
an order for genomic testing. Participants in the study were asked to complete three
online surveys administered by Survey Sciences Group (Ann Arbor, MI). The three
surveys included a baseline survey which was administered after submission of the
sample but prior to receipt of DTC PGT results, two to three week follow up after receipt
of DTC PGT results, and six-month follow up after receipt of DTC PGT results.
Sample
The total sample for the PGen study included 1,464 participants who engaged in
DTC PGT. The sample used for this study consisted of the 887 participants who
participated in all three of the surveys and completed all analyzed items and scales. These
887 participants were split into three age groups, 19-39 year olds, 40-59 year olds, and
60+ year olds. This division was based on other studies with the data set (Ostergren et al.
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2015). Demographic characteristics for the 887 individuals included in our study are
depicted in Table 3.1.
Table 3.1
Demographic and Socioeconomic Characteristics by Age Group (%)
Age Group (years)
19-39
40-59
60+
Overall
Number
350
314
223
887
Mean Age (years)
30.22
49.51
66.92
46.28
Female
56.9
64.1
56.1
59.2
Relationship status
Single
36.3
14.6
5.4
20.8
Married/Partnered
58.6
71.5
75.8
67.4
Divorced/Separated/Widowed
5.1
14.0
18.9
11.7
Adopted
6.0
7.9
2.2
5.7
Have Biological Children
18.9
60.6
78.5
48.6
Ethnicity
Hispanic/Latino
6.9
5.1
1.3
4.8
Racea
Asian
9.7
2.2
0.0
4.6
Black or African American
3.7
3.8
1.3
3.2
White
86.6
92.4
95.5
90.9
Other Race
11.9
7.0
7.1
9.0
Highest Level of Education
Less Than College
17.2
20.7
25.1
20.4
College Degree
37.1
31.1
17.9
30.2
Some Graduate School
35.1
34.2
40.0
36.0
Doctoral Equivalent
10.5
14.0
17.0
13.5
Income in the past 12 Months
<$100,000
58.9
48.4
58.4
55.9
$100,000-199,999
29.1
36.3
28.1
31.4
≥$200,000
10.0
15.3
13.6
12.8
Note: aSome participants indicated more than one race thus the totals exceed 100%.
Measures
The major variables of interest in this study include: Genetic Knowledge (GK),
Self-Rated Genetic Competency (SRGC), Genetic Personal Utility (GPU), and Genetic
Response Efficacy (GRE). The term genetic knowledge describes the factual science,
familial inheritance, and technology information related to genetics and genomics as it is
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known to the respondent. In this study, genetic knowledge is measured using a nineitem, true or false instrument that is a combination of selected items from previous
studies of genetic knowledge (Bowling et al., 2008; Furr & Kelly, 1999; Molster,
Charles, Samanek, & O’Leary, 2009; Smerecnik, 2010). Genetic knowledge is measured
at baseline and at the six-month follow up, and is expressed as a percentage of correct
answers.
The SRGC Scale is composed of five seven-option Likert type items that evaluate
a respondent’s beliefs in their own ability to understand genetic information. The SRGC
Scale was administered at baseline and at the six month follow up, higher scores indicate
stronger beliefs in their own abilities. The Genetic Personal Utility Scale (GPUS) is
composed of three questions with a five-option Likert-type scale (Bloss et al., 2010).
These GPUS questions are asked in the two to three week follow up and six-month
follow-up questionnaires. The GPUS questions address a respondent’s perception of the
usefulness of the genetic testing results regarding their health. Higher scores indicate a
greater perceptions of usefulness. A five-option Likert-type single item is used to
measure GRE in respondents (Wade et al., 2012). The item is included in the baseline and
six-month follow-up questionnaires, a higher score indicates greater belief that genetic
testing has benefits for improving or maintaining health.
Statistical Analysis
A mixed between-within subjects, repeated measures analysis of variance
(ANOVA) was used to compare the changes between initial and follow-up measures of
Genetic Knowledge, Genetic Response Efficacy, Self-Rated Genetic Competency, and
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Genetic Personal Utility among the three age groups. When homogeneity of covariance
was not satisfied, Pillai’s Trace was used to increase the robustness and power of the
analysis. Bonferroni corrections were conducted for post hoc analyses when appropriate.
In order to identify genetic testing decision-making influencers, participant ratings
of importance for 19 aspects of genetic testing were evaluated by factor analysis with
Oblimin (Oblique) rotation to identify any scoring patterns among the sample. The means
of the three age groups for the resulting factors were compared using ANOVA. When
homogeneity of variance was not satisfied, Welch’s adjusted F ratio was evaluated,
correcting for inequalities in variance among groups (Welch, 1951). In addition, GamesHowell post hoc tests were performed using an a priori alpha level of .05. Analyses were
conducted using IBM SPSS Statistics, Version 23.0.
Results
Descriptive statistics for Genetic Knowledge, Self-Rated Genetic Competency,
Genetic Response Efficacy, and Genetic Personal Utility are presented in Table 3.2.
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Table 3.2
Genetic Knowledge, Perceptions, and Beliefs Descriptive Statistics by Age Group
Scale
19-39 years
40-59 years
60+ years
Overall
Genetic Knowledge
Baseline
92.00 (9.56) 90.90 (10.69) 88.99 (11.16) 90.85 (10.44)
6 month follow-up 92.95 (9.28)
91.85 (9.54) 89.89 (11.46) 91.79 (10.02)
Self-rated Genetic
Competency
Baseline
5.80 (1.17)
5.85 (1.13)
5.81 (0.97)
5.82 (1.10)
6 month follow-up
5.63 (1.10)
5.59 (1.11)
5.35 (1.05)
5.55 (1.09)
Genetic Personal
Utility
2-3 week follow-up
3.96 (0.77)
3.92 (0.86)
3.76 (0.98)
3.89 (0.86)
6 month follow-up
3.69 (0.90)
3.77 (0.95)
3.58 (1.05)
3.69 (0.96)
Genetic Response
Efficacy
Baseline
3.49 (0.98)
3.43 (0.97)
3.37 (0.94)
3.44 (0.97)
6 month follow-up
3.23 (1.05)
3.42 (1.09)
3.22 (1.13)
3.30 (1.09)
Note: Values expressed as Mean (SD)

Comparing Genetic Knowledge and Perceptions Measures Among Age Groups
There was not a significant interaction between time and age group membership
on genetic knowledge scores, F (2, 885) = 0.002, p = .998. There was a significant effect
of time on genetic knowledge, F (1, 886) = 5.749, p = .017. All of the age groups showed
an increase in genetic knowledge scores between the baseline and six month follow-up
surveys. Age group membership had a significant effect on differences in genetic
knowledge scores, F (2, 885) = 8.862, p < .001. Post hoc analyses indicated a significant
difference in change in genetic knowledge scores when comparing the 60 + year old
group with both the 19-39 year old group (M=.274, 95% CI [.118, .430], p<.001) and the
40-59 year old group (M=.174, 95% CI [.015, .334], p<.05).
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There was a significant interaction effect for time and age group membership on
SRGC, F (2, 885) = 4.169, p = .016. Post hoc tests show no difference in means between
the 19-39 year old and 40-59 year old groups (M=.000, 95% CI [-.173, .172], p=1.00)
while there was a difference between the 60+ year old group and the 19-39 year old
group (M=.135, 95% CI [-.325, .055], p<.269) and the 40-59 year old group (M=.135,
95% CI [-.329, .059], p<.288). There was also a significant effect of time on SRGC, F (1,
886) = 55.159, p<.001. All of the SRGC scores decreased over time regardless of the age
group. Age group membership was not significant, F (2, 885) = 1.772, p = .171.
There was also a significant interaction effect for time and age group membership
on GRE, F (2, 885) = 3.523, p = .030. The main effect for time on GRE was significant,
F (1, 886) = 11.175, p = .001. Genetic Response Efficacy scores were higher at baseline
than they were after six months, regardless of age group. There was no significant main
effect for age group membership on GRE, F (2, 885) = 1.705, p = .182.
The interaction effect for time and age group membership on GPUS was not
significant, F (2, 885) = 2.045, p = .130. However, there was a significant effect for time
on GPUS, F (1, 886) = 59.450, p < .001, the scores for GPUS were higher at the two to
three week survey than at the six month follow up. There was also a significant effect for
age group membership, F (2, 885) = 3.307, p = .037. There were significant differences
between the 60+ year olds and both the 19- 39 year olds (M=.155, 95% CI [.016, .294],
p<.029) and the 40-59 year olds (M=.174, 95% CI [.031, .316], p<.017), indicating that
the GPUS scores for the 60+ year olds were significantly lower than both of the other age
groups.
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Examining Patterns in Decision-making Influences
The 19 items that focused on reasons to test and factors influencing testing
decisions were subjected to factor analysis. The screeplot illustrated a clear break after
the second factor. Using Catell’s (1966) scree test, it was decided to retain two factors
for further evaluation. Table 3.3 illustrates the pattern and structure matrices for the twofactor solution with a 0.4 pattern coefficient cut off.
The two-factor solution explained a total of 32.8% of variance, with Factor 1
contributing 22.3%, and Factor 2 contributing 10.5%. The rotated solution revealed the
presence of simple structure (Thurstone, 1947), with both factors showing a number of
strong loadings and each variable loading substantially onto only one factor.
The interpretation of the two factors identified two unique patterns to the
loadings. Items focused on health and the future loaded strongly onto Factor 1. Items
more aligned with the curiosity and intrigue of genetics loaded strongly onto Factor 2.
There was a weak correlation between the two factors (r = .203). These results suggest
that the components can be evaluated separately. Two factor scores were created by
averaging the items from each factor.
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Non-Loading

Curiosity and Intrigue

Health and Future

Table 3.3
Pattern and Structure Matrix for Factor Analysis with Oblimin Rotation
Pattern
Structure
coefficients coefficients
Factor
Factor
Survey Item
1
2
1
2 Communalities
.645
.812 -.052 .801 .113
 Improve my health
 Create a better plan for the
.598
.780 -.033 .773 .125
future
 Finding out about personal risk
.583
.779 -.134 .769 .150
for specific diseases
.592
.771 -.007 .752 .024
 Health-related
 Predict whether or not I'm going
.475
.693 -.018 .689 .122
to get a particular disease
 Individual response to different
.461
.680 -.003 .679 .135
types of medications
 Personal interest in genetics in
-.098 .557 .015 .538
.298
general
 The convenience of being tested
.037 .526 .143 .533
.286
at home
 The education materials made
.116 .508 .219 .531
.295
available through the company
 Desire to learn more about my
.118 .494 .218 .518
.282
genetics because I am adopted
 Curiosity about my genetic
-.081 .478 .016 .462
.219
makeup
 The service seemed like it would
-.311 .455 .345 .447
.247
be fun and entertaining
 Might receive unwanted
.372 .078 .419 .378
.156
information
 Information about the risk for my
.358 .305 .388 .153
.265
current or future children
.227 .128 .253 .174
.080
 Privacy of my genetic information
 Other members of my family are
.021 .396 .297 .415
.161
using personal genomic services
 Learn about my genetics because I
.266 .394 .101 .400
.268
have limited information about
family health history
 Learn about my genetic makeup
.222 .369 -.219 .392
.219
without going through a physician
-.018 .321 .047 .317
.101
 Cost of services
Note: Major loadings for each item included in factors are bolded.
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Age group membership was examined for the two factors using ANOVA.
Descriptive statistics for each of the factors for the age groups and overall are found in
Table 3.4. Though the assumption of homogeneity of variance was not satisfied. The
effect of age group membership was significant, Welch’s F (2, 513.34) = 5.012, p < .01.
Post hoc tests indicated that the mean scores for the 60+ year old age group were
significantly different from the 19-39 year old and 40-59 year old groups for the Health
and Future Factor (p = .006 and p = .028 respectively). There was not a significant
difference in the Curiosity and Intrigue scores for the three age groups: F (2, 884) =
2.011, p = .134.
Table 3.4
Descriptive Statistics for Two Factors by Age Group
19-39 years old 40-59 years old

60+ years old

Overall

Health and Future

2.37 (0.46)

2.36 (0.51)

2.23 (0.60)

2.33 (0.52)

Curiosity and Intrigue

2.47 (0.40)

2.41 (0.41)

2.47 (0.41)

2.45 (0.41)

Note. Values expressed as Mean (SD)
Discussion
When examining the differences among age groups related to genetic knowledge,
perceptions, and factors that shape decision-making there are differences between the 60+
year old group and the younger age groups. Older adults were found to have significantly
lower genetic knowledge scores, and age group membership was also found to be a
significant factor in differences in perceptions of genetic utility. Self-rated genetic
competency, and genetic personal utility measures had significant decreases over time,
while Genetic Knowledge increased significantly over time. Thus there were differences
in perceptions of genetics among older adult participants in the PGen study when
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compared with other age groups. The factors that influenced the decision to engage in
DTC PGT loaded into two factors, ‘Health and Future’ and ‘Curiosity and Intrigue.’
Older adult groups had significantly lower scores in the ‘Health and Future’ factor,
indicating that older adults may be less likely to be concerned with the ‘Health and
Future’ aspects of testing than the other age groups. This may be an effect of fatalism on
the part of older adults, or perhaps they do not place a high value on the future
possibilities for genetic information on their own health.
The results of this study further support previous studies’ assertions that there are
clear differences in genetic knowledge among different age groups (Ashida et al., 2011;
Carere et al., 2015; Morren et al., 2007; Ostergren et al., 2015). The results of
comparisons of genetic knowledge show that the 60+ year olds were more likely to have
statistically significant lower genetic knowledge scores than the other two groups. As
previously discussed, these findings could be associated with limited genetics education
exposure even with 57% of this age group reporting having had some graduate education.
These results must be examined in the overall change that is exhibited in knowledge, the
change is scores, while statistically significant, is not necessarily a meaningful change as
it is small in comparison to the overall scoring for the genetic knowledge questions. Even
in light of this, the finding highlights the need to seek out opportunities and methods to
educate older adults about genetics so that they are better able to engage with the genetic
technology that is becoming more available in society clinically and commercially.
The decreases of the Self-Rated Genetic Competency scores over time may
indicate that the experience of using DTC PGT may have led the participants to
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reconsider their abilities to interpret the genetic material. Response Efficacy measures
also decreased over time, possibly indicating that the receipt of the DTC PGT results may
have caused the study participants to change their views on the ability of genetic level
information to improve their health. This change could also be related to the fact that
their DTC PGT results may not have any genomic findings that were new to the
participants or that they felt like they could do anything about after receiving the results.
There was also a statistically significant decrease in the respondents’ GPUS
scores. The decrease of the means of these scores across all three age groups does suggest
that there may be a feeling of inability to connect the PGT results directly to health
actions among all age groups. Further study is needed to better understand this
possibility. It would be very interesting to understand if the decrease in the personal
utility scale scores relates to specific factors or is the decrease a result of a failure to meet
the participants’ anticipated utility prior to receiving the results.
While understanding the knowledge and perception differences among the three
age groups is helpful, in order to move a step closer to the actual decision-making
process, it is important to understand the driving motivations for engaging in DTC PGT.
The identification of the two factors capturing the participants’ reasons to test is
important because it highlights two distinct areas of interest that were unique among the
participants. The Health and Future-Oriented factor was the stronger loading factor,
highlighting the importance that participants placed on the health-related aspects of the
genomic testing. The second factor is best characterized as being Curiosity and IntrigueOriented which captures the elements of DTC PGT that are more related to the novelty
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and, to some extent, recreational engagement that some participants find most appealing.
When these two factors are compared across the age groups, the 60+ year old group was
significantly less likely to rate the Health and Future-related aspects of DTC PGT as high
as the other two age groups were. This finding may be tied with the differences seen in
the genetic knowledge score among the age groups; however, it is also possible that there
are other factors of importance to older adults that were not captured by the surveys.
When looking at the second factor scores, ‘Curiosity and Intrigue,’ there is no statistical
difference among the three age groups. This may be a result of the fact that this test is
not being completed in a clinical setting and that the aspects captured by this factor are
baseline aspects that all participants in DTC PGT find important. Both of these factors
could be examined more completely in an effort to fully understand what drives
participants to engage in the DTC PGT.
The use of the PGen data set provides great benefits in providing a high quality
repeated measures survey study with a large sample of respondents for the exploration of
these questions, although it should be noted that there are several limitations of the study
that must be acknowledged. First and foremost, these results give some insight into the
different age groups, but they are somewhat limited in their broader application because
of the fact that the sample is predominantly white (90.9%), married/partnered (67.4%),
largely female (59.2%) and affluent (44.1% reporting annual earnings > $100,000). It is
also imperative to realize that the entire sample is self-selected. Translation of these
findings will require other study designs, more diverse populations, and comparisons of
the findings to better support generalizable research findings.
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In conclusion, there are significant differences in the genetic knowledge and
perceptions of the 60+ year old age group when compared with the 19-39 year old and
40-59 year old age groups. These differences, even while observed in this group of DTC
PGT participants, offer some clear indications that more research on the older adult
population with regard to genetics and genomics knowledge, perceptions, and decisionmaking needs to be done. Furthermore, there is a need for similar studies to examine
those persons who are engaging in clinical genetic or genomic testing programs beyond
DTC PGT.
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CHAPTER FOUR:
USING AGE AND PROTECTION MOTIVATION THEORY TO EXPLORE
PERSONAL GENOMIC TESTING RESULT UTILIZATION
Abstract
Background: Direct-to-consumer personal genomic testing (DTC PGT) is changing the
way that people are able to access genetic level information. Testing results from DTC
PGT companies come in a different format than those from clinical testing and healthcare
providers. Consumers who use DTC PGT are getting the genetic-level information and
are sometimes making social and financial health-related decisions based on their own
perceptions of the meanings of the results.
Objectives: To explore the use of the Protection Motivation Theory (PMT) concepts as a
way to better understand behaviors of results utilization in DTC PGT customers through
looking at trends among three age groups.
Methods: We analyzed data from the Impact of Personal Genomics Study, which were
collected before DTC PGT results were received, and again at two to three week and six
month follow-up intervals following participants’ receipt of DTC PGT results.
Contingency tables and descriptive statistics were used to examine trends in PMT
concepts and uses of DTC PGT results among three age groups. Four outcomes were
examined: 1) discussing DTC PGT results with someone, 2) making changes in health
insurance, 3) making changes in financial or retirement plans, and 4) making changes in
advance planning.
Results: Those who engaged in making changes to their retirement and advance
directives were more likely to be of the 60+ group than any other group. There were no
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large differences in the ratings of the PMT theory concepts, those who engaged in the
four target behaviors were more likely to have higher response efficacy and self-efficacy
ratings while having moderate to lower perceived severity ratings and moderate to higher
perceived vulnerability ratings.
Conclusions: The significance of the application of the PMT is valuable in helping to
better understand who and, possibly in the future, why some DTC PGT participants are
responding the way that they do to their DTC PGT results. These results can help to
support DTC PGT participants in decision-making by offering a better understanding
about what drives their decisions. These findings also suggest that DTC PGT results are
being used when making decisions that are important including, financial and advance
planning decisions. The link between perceptions of results and self and these outcomes
is important in further describing the context of decision-making in genomics and across
age groups.
Keywords: Protection Motivation Theory, Direct-to-Consumer Personal Genetic
Testing, Genetics, Advance Planning, Genomics
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Using Age and Protection Motivation Theory to Explore Personal Genomic Testing
Result Utilization
Introduction
As genetic information has become a larger part of the health landscape, there
have been numerous policy and guideline changes that are intended to address concerns
about privacy and discrimination related to genetic findings (eg. Genetic Information
Nondiscrimination Act 2008) (Green, Lautenbach, & McGuire, 2015). Direct-toconsumer personal genomic testing (DTC PGT) carries with it a variety of similar and
also unique concerns when compared with clinical genetic testing. Direct-to-consumer
personal genomic testing services do not provide individualized genetic counseling to
accompany their results, and while the testing services do offer education related to
testing and results, the service model leaves open the possibility of misinterpretation on
the part of the result recipients. There have been several studies to emerge from the
Impact of Personal Genomics (PGen) data that indicate differences in various aspects of
consumer understanding, knowledge, and comfort with the genetic information (Carere et
al., 2014; Carere, VanderWeele, et al., 2015; Ostergren et al., 2015). Understanding the
way that genomic testing results may lead to changes in health behaviors is an important
part of evaluating the full influence of genomic level information (Christensen et al.,
2015; Zick et al., 2005). Furthermore, understanding how consumers’ perceptions related
to genomics may influence the actions they take with their genomic information may
assist healthcare providers, policy makers, and scientists to better understand and support
individuals who engage in DTC PGT (Kaufman, Bollinger, Dvoskin, & Scott, 2012;
McBride et al., 2009; McBride, Wade, & Kaphingst, 2010). Previous studies have
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examined the influence of genetic testing on individuals’ purchasing of insurance or
management decisions and have reported mixed findings (Armstrong et al., 2003; Zick,
Smith, Mayer, & Botkin, 2000; Zick et al., 2005). Those previous studies did not,
however, consider the perceptions or the ages of the participants as indicators of these
behaviors, nor did they study DTC PGT. This article evaluates differences in the DTC
PGT result utilization behaviors as they differ among different age groups (19-39, 40-59,
and 60+). It also explores the use of the Protection Motivation Theory (PMT) (Maddux &
Rogers, 1983; Rogers 1983) as a way to explain the result utilization behaviors of DTC
PGT customers.
Protection Motivation Theory
The PMT, in its revised version, features three main concepts: threat appraisal,
coping appraisal, and protection motivation (Floyd, Prentice-Dunn, & Rogers, 2000;
Maddox & Rogers, 1983; Norman, Boer, & Seydel, 2005; Rogers, 1983). Threat
appraisal is best described as the combination of the perceived severity and the perceived
vulnerability related to the negative outcome of concern (Rogers, 1983). This negative
outcome could be a disease diagnosis, injury, or some other negative experience that can
be avoided. Perceived severity is defined in terms of a person’s beliefs about the potential
bodily harm, interpersonal threats, and intrapersonal threats that would result from the
negative outcome. Perceived vulnerability is defined in terms of a person’s beliefs that
they may experience the negative outcome.
Coping appraisal is described as the combination of perceived self-efficacy and
response efficacy related to the negative outcome of concern (Maddox & Rogers, 1983;
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Rogers, 1983). Response efficacy is defined as a person’s beliefs related to the
effectiveness of coping responses. Self-efficacy is defined as a person’s beliefs about
their ability to perform or not perform a behavior (e.g., a recommended response to the
negative outcome of concern).
Protection motivation is best described as the intent to adopt a recommended
course of action or engage in a protective behavior to limit the likelihood of experiencing
the negative outcome (Maddux & Rogers, 1983; Rogers, 1975, 1983). The PMT is based
on the assumption that there is a positive linear relationship among: severity of the threat,
vulnerability to the threat, the ability to cope with the threat, and that engaging in the
behavior of concern will decrease risks of the negative outcome (Rogers, 1983). For the
purposes of this study, protection motivation is defined as engaging in disclosure of
results or making changes in insurance, retirement or financial plans, or advance
planning.
Protection Motivation Theory and Genetics
Protection motivation theory has been applied to a variety of studies, several of
which have genetic relevance either directly with genetic testing, genetic information, or
by featuring some aspect of family inheritance of diseases (Azzarello, Dessureault, &
Jacobsen, 2006; Fisher, Bonner, Biankin, & Juraskova, 2012; Helmes 2002; Ralph et al.,
2014; Vadaparampil et al. 2004; Wright, French, Weinman, & Marteau, 2006). Three
distinct areas of behaviors that have been studied using the PMT with relevance to this
study include: screening and preventive behaviors, use of genetic testing information to
make health changes, and engagement in genetic testing.
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In the area of screening and preventive behaviors, self-efficacy and perceived risk
were found to be significant contributors to making changes in preventative health
behaviors related to melanoma. (Azzarello, Dessureault, & Jacobsen, 2006). In a
population of first-degree relatives of men with prostate cancer, self-efficacy, income and
age were found to be contributors to making changes (Vadaparampil et al. 2004). These
findings were consistent with the results of other research in health-protective behaviors.
In examining the influence of genetic risk on smoking, self-efficacy was shown to have a
significant effect on intentions to quit smoking (Wright, French, Weinman, & Marteau,
2006). Among smokers, knowledge of increased genetic risk for lung cancer is associated
with greater intentions to engage in smoking cessation activities when compared with
those without any genetic risk knowledge. Protection Motivation Theory has also been
applied to the preference for selective estrogen reuptake modulators (SERM) among
women with an increased genetic risk of breast cancer. Ralph and associates (2014)
evaluated the relationships among PMT concepts and intentions to engage in SERM
treatment identifying perceived vulnerability, perceived severity, and response efficacy as
each making a significant unique contribution to the explained variance.
Helmes (2002) assessed the PMT’s components for predictive applications in
understanding womens’ motivations to engage in genetic testing. The study did not fully
support the use of the PMT as a predictive framework for genetic testing motivation
assessment; however, there was a clear association with perceived risk and an increased
likelihood to engage in testing. Fisher, Bonner, Biankin, and Juraskova (2012) evaluated
the application of PMT constructs as possible predictors of whole genome sequencing
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(WGS) screening intentions; finding that response efficacy, response costs, and selfefficacy each made a significant unique contribution to explained variance in the model.
The PMT has been applied to a variety of genetic and genomic-related behaviors,
but there is limited assessment of PMT’s applicability to DTC PGT, specifically the
disclosure of DTC PGT results or utilization of the DTC PGT results to make changes in
insurance, retirement, and advance planning behaviors. These areas are not currently
addressed in the literature. This study explores the application of the PMT to genetic
information disclosure and utilization behaviors among three age groups (19-39, 40-59,
60+). Our aim for this article is to explore the applicability of the PMT to the utilization
of DTC PGT results, and to describe age group differences in use of the DTC PGT
results.
Design and Methods
Sample
The PGen study was approved by the University of Michigan School of Public
Health Institutional Review Board and the Partners Human Research Committee. Each
study participant completed an electronic informed consent prior to study enrollment.
The specific details of design and data collection for the PGen study have been reported
previously (Carere et al., 2014; Lehmann et al., 2012).
The sample was recruited between March and July 2012 from among new directto-consumer genomic testing customers of the 23andMe and Pathway Genomics services.
The study consisted of three online surveys that were administered by Survey Sciences
Group (Ann Arbor, MI). These surveys included a baseline survey that was administered
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following the participant’s submission of a sample but prior to receipt of DTC PGT
results, the two follow-up surveys were administered at two to three weeks and sixmonths after receipt of the DTC PGT results.
Table 4.1
Demographic and Socioeconomic Information by Group (%)
19-39 Years 40-59 Years 60+ Years Overall
Number
350
314
223
888
Mean Age (years)
30.22
49.51
66.92
46.28
Female
56.9
64.1
56.1
59.2
Relationship status
Married/Partnered
58.6
71.5
75.8
67.4
Have Biological Children
18.9
60.6
78.5
48.6
a
Race
American Indian/Native
3.1
1.9
3.6
2.8
Alaskan
9.7
2.2
.0
4.6
Asian
3.7
3.8
1.3
3.2
Black or African American
1.4
.3
.4
.8
Hawaiian or Pacific Islander
86.6
92.4
95.5
90.9
White
7.4
4.8
3.1
5.4
Other Race
Highest Level of Education
17.2
20.7
25.1
20.4
Less Than College
37.1
31.1
17.9
30.2
College Degree
35.1
34.2
40.0
36.0
Some Graduate School
10.5
14.0
17.0
13.5
Doctoral Equivalent
Current Employment Status
81.2
78.4
39.0
69.6
Employed
.6
11.1
63.2
20.0
Retired
12.6
16.5
6.3
12.4
Unemployed
20.3
1.6
.0
8.6
Student
Household Income Past 12
58.9
48.4
58.4
55.9
Months <$100,000
Note: aSome participants indicated more than one race thus the totals exceed 100%.
The PGen study included a total of 1,464 participants who engaged in DTC PGT.
The sample used for this study consisted of 887, of those participants who completed the
baseline, two to three week follow-up, and six month follow-up surveys. Table 4.1 offers
descriptive demographic statistics for the sample included in this analysis.
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Measures of Perception Motivation Theory Concepts
Perceived severity. The measure of perceived severity is an 11-item instrument
with a four-option, Likert-type scale with high reliability (α=.82) and robust construct
validity (Chung et al., 2009). The scale gathers information regarding the respondents’
beliefs about the severity of their personal genomic testing results. These questions are
included in the six-month follow-up questionnaire, a higher score on this scale indicates a
higher perceived severity of the DTC PGT results.
Perceived vulnerability. The measure of perceived vulnerability is composed of
nine items with a five option Likert-type scale that gathers information about
respondents’ perceived risk of having a genetic-linked disease. These items do not relate
to the actual results from the testing company and are solely based on the respondents’
beliefs about their own vulnerability to genetic disease. These questions are included in
the six month follow-up questionnaire. A higher value indicates a higher perception of
vulnerability to having a genetic-linked disease.
Response efficacy. A five option Likert-type single item is used to measure
response efficacy in respondents (Wade et al., 2012). The item is included in the six
month follow-up questionnaire. A higher score on this item indicates a stronger belief
that the DTC PGT results would be helpful in improving health or avoiding illness.
Self-efficacy. The measurement for self-efficacy in respondents is a five item
seven point Likert-type scale (Parrott, Silk, & Condit, 2003). The scale has a high
reliability (α=.86) (McBride et al., 2009). This scale is included in the six-month followup questionnaire. Those respondents with a higher score on this scale believe that they
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are more able to accurately engage with their genomic results and understand the results’
meanings on their own.
Post Result Receipt Behaviors. The four outcome variables: 1) discussing DTC
PGT results with someone else, 2) making a change in their insurance coverage in
response to the DTC PGT results, 3) making a change in their retirement or financial
plans in response to DTC PGT results, and 4) making a change in their advance planning
as a response to their DTC PGT results are all single items. They are asked using yes or
no answer choices on the six month follow up survey.
Statistical Analysis
Descriptive statistics were calculated for each of the analyzed items and
contingency tables were constructed for each of the four post result receipt behaviors by
each of the PMT concepts. Due to low cell counts in all of the contingency tables chisquare analyses were inappropriate. All analyses were run using IBM SPSS Statistics
23.0.
Results
Descriptive Statistics
The self-reported percentages of use of the PGT results are displayed in Table 4.2
along with the PMT conceptual measure averages included in the analysis.
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Table 4.2
Personal Genomic Testing Result Usage and Protection Motivation Theory Concept
Descriptive Statistics by Age Group
19-39 years
40-59 years 60+ years Overall
a
Intended to discuss results
96.0 (336)
94.0 (296) 97.8 (218) 95.7 (850)
Discussed resultsa
96.6 (338)
93.0 (293) 94.6 (211) 94.8 (842)
a
Changed insurance coverage
0.3 (1)
0.3 (1)
1.3 (3)
0.6 (5)
Changed financial/retirementa
0.6 (2)
2.2 (7)
4.5 (10)
2.1 (19)
a
Changed advance planning
1.1 (4)
2.2 (7)
8.1 (18)
3.3 (29)
Perceived Severity Scaleb
1.85 (0.37) 1.91 (0.41) 1.86 (0.40) 1.88 (0.39)
Perceived Vulnerability Scaleb 22.67 (5.17) 23.56 (5.21) 23.44 (6.72) 23.18 (5.62)
Response Efficacyb
3.23 (1.05) 3.42 (1.09) 3.22 (1.13) 3.30 (1.09)
Genetic Self-Efficacyb
5.63 (1.10) 5.59 (1.11) 5.35 (1.05) 5.55 (1.09)
Note. aItem expressed in percent (n). bItem expressed in mean (SD).
The distributions of the participant ratings for the four concepts of the PMT are
depicted in the contingency tables organized by each of the four post result receipt
behaviors among each of the age groups (Tables 4.3-4.6).

Total

60+

40-59

19-39

Table 4.3
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal
Genomic Testing Results
Response Efficacy
1
2
3
4
5
No
1 (8.3%)
3 (25.0%)
3 (25.0%)
5 (41.7%)
0 (0.0%)
Yes
23 (6.8%)
56 (16.6%) 104 (30.8%)
126 (37.3%)
29 (8.6%)
Total
24 (6.9%)
59 (16.9%) 107 (30.6%)
131 (37.4%)
29 (8.3%)
No
2 (9.1%)
4 (18.2%)
9 (40.9%)
7 (31.8%)
0 (0.0%)
Yes
19 (6.5%)
33 (11.3%)
85 (29.0%)
107 (36.5%)
49 (16.7%)
Total
21 (6.7%)
37 (11.7%)
94 (29.8%)
114 (36.2%)
49 (15.6%)
No
3 (25.0%)
3 (25.0%)
5 (41.7%)
1 (8.3%)
0 (0.0%)
Yes
23 (10.9%)
20 (9.5%)
68 (32.2%)
78 (37.0%)
22 (10.4%)
Total
26 (11.7%)
23 (10.3%)
73 (32.7%)
79 (35.4%)
22 (9.9%)
No
6 (13.0%)
10 (21.7%)
17 (37.0%)
13 (28.3%)
0 (0.0%)
Yes
65 (7.7%) 109 (12.9%) 257 (30.5%)
311 (36.9%)
100 (11.9%)
Total
71 (8.0%) 119 (13.4%) 274 (30.9%)
324 (36.5%)
100 (11.3%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.3 continued
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal
Genomic Testing Results
Self-Efficacy Rating
1
2
3
4
5
No
0 (0.0%)
0 (0.0%)
1 (8.3%)
6 (50.0%)
5 (41.7%)
Yes
4 (1.2%)
8 (2.4%)
32 (9.5%)
97 (28.7%)
197 (58.3%)
Total
4 (1.1%)
8 (2.3%)
33 (9.4%)
103 (29.4%)
202 (57.7%)
No
1 (4.5%)
2 (9.1%)
2 (9.1%)
8 (36.4%)
9 (40.9%)
Yes
5 (1.7%)
3 (1.0%)
20 (6.8%)
109 (37.2%)
156 (53.2%)
Total
6 (1.9%)
5 (1.6%)
22 (7.0%)
117 (37.1%)
165 (52.4%)
No
1 (8.3%)
1 (8.3%)
4 (33.3%)
3 (25.0%)
3 (25.0%)
Yes
3 (1.4%)
3 (1.4%)
23 (10.9%)
88 (41.7%)
94 (44.5%)
Total
4 (1.8%)
4 (1.8%)
27 (12.1%)
91 (40.8%)
97 (43.5%)
No
2 (4.3%)
3 (6.5%)
7 (15.2%)
17 (37.0%)
17 (37.0%)
Yes
12 (1.4%) 14 (1.7%)
75 (8.9%)
294 (34.9%)
447 (53.1%)
Total
14 (1.6%) 17 (1.9%)
82 (9.2%)
311 (35.0%)
464 (52.3%)
Perceived Severity Rating
1
2
3
No
5 (41.7%)
6 (50.0%)
1 (8.3%)
50 (14.8%)
Yes
266 (78.7%)
22 (6.5%)
Total
55 (15.7%)
272 (77.7%)
23 (6.6%)
No
4 (18.2%)
14 (63.6%)
4 (18.2%)
47 (16.0%)
Yes
222 (75.8%)
24 (8.2%)
Total
51 (16.2%)
236 (74.9%)
28 (8.9%)
No
3 (25.0%)
7 (58.3%)
2 (16.7%)
36 (17.1%)
Yes
158 (74.9%)
17 (8.1%)
Total
39 (17.5%)
165 (74.0%)
19 (8.5%)
No
12 (26.1%)
27 (58.7%)
7 (15.2%)
133 (15.8%)
Yes
646 (76.7%)
63 (7.5%)
Total
145 (16.3%)
673 (75.8%)
70 (7.9%)
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Total

60+

40-59

19-39

Table 4.3 continued
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal
Genomic Testing Results
Perceived Vulnerability Rating
1
2
3
4
5
No
0 (0.0%)
3 (25.0%)
7 (58.3%)
2(16.7%)
0 (0.0%)
Yes
5 (1.5%)
30 (8.9%)
165 (48.8%)
128 (37.9%)
10 (3.0%)
Total
5 (1.4%)
33 (9.4%)
172 (49.1%)
130 (37.1%)
10 (2.9%)
No
0 (0.0%)
3 (13.6%)
11 (50.0%)
6 (7.3%)
2 (9.1%)
Yes
2 (.7%)
26 (8.9%)
133 (45.5%)
122 (41.8%)
9 (3.1%)
Total
2 (.6%)
29 (9.2%)
144 (45.9%)
128 (40.8%)
11 (3.5%)
No
0 (0.0%)
3 (25.0%)
6 (50.0%)
2 (16.7%)
1 (8.3%)
Yes
0 (0.0%)
30 (14.2%)
94 (44.5%)
70 (33.2%)
17 (8.1%)
Total
0 (0.0%)
33 (14.8%)
100 (44.8%)
72 (32.3%)
18 (8.1%)
No
0 (0.0%)
9 (19.6%)
24 (52.2%)
10 (21.7%)
3 (6.5%)
Yes
7 (.8%)
86 (10.2%)
392 (46.6%)
320 (38.0%)
36 (4.3%)
Total
7 (.8%)
95 (10.7%)
416 (46.9%)
330 (37.2%)
39 (4.4%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.4
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Health Insurance
Response Efficacy
1
2
3
4
5
No
24 (6.9%)
59 (16.9%) 106 (30.4%) 131 (37.5%)
29 (8.3%)
Yes
0 (0.0%)
0 (0.0%)
1 (100.0%)
0 (0.0%)
0 (0.0%)
Total
24 (6.9%)
59 (16.9%) 107 (30.6%) 131 (37.4%)
29 (8.3%)
No
21 (6.7%)
37 (11.8%)
94 (29.9%) 114 (36.3%)
48 (15.3%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (100.0%)
Total
21 (6.7%)
37 (11.7%)
94 (29.8%) 114 (36.2%)
49 (15.6%)
No
26 (11.8%)
22 (10.0%)
73 (33.2%)
79 (35.9%)
20 (9.1%)
Yes
0 (0.0%)
1 (33.3%)
0 (0.0%)
0 (0.0%)
2 (66.7%)
Total
26 (11.7%)
23 (10.3%)
73 (32.7%)
79 (35.4%)
22 (9.9%)
No
71 (8.0%) 118 (13.4%) 273 (30.9%) 324 (36.7%)
97 (11.0%)
Yes
0 (0.0%)
1 (20.0%)
1 (20.0%)
0 (0.0%)
3 (60.0%)
Total
71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%)
Self-Efficacy Rating
1
2
3
4
5
No
4 (1.1%)
8 (2.3%)
33 (9.5%) 102 (29.2%) 202 (57.9%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (100.0%)
0 (0.0%)
Total
4 (1.1%)
8 (2.3%)
33 (9.4%) 103 (29.4%) 202 (57.7%)
No
6 (1.9%)
5 (1.6%)
22 (7.0%) 116 (36.9%) 165 (52.5%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (100.0%)
0 (0.0%)
Total
6 (1.9%)
5 (1.6%)
22 (7.0%) 117 (37.1%) 165 (52.4%)
No
4 (1.8%)
4 (1.8%)
26 (11.8%)
91 (41.4%)
95 (43.2%)
Yes
0 (0.0%)
0 (0.0%)
1 (33.3%)
0 (0.0%)
2 (66.7%)
Total
4 (1.8%)
4 (1.8%)
27 (12.1%)
91 (40.8%)
97 (43.5%)
No
14 (1.6%)
17 (1.9%)
81 (9.2%) 309 (35.0%) 462 (52.3%)
Yes
0 (0.0%)
0 (0.0%)
1 (20.0%)
2 (40.0%)
2 (40.0%)
Total
14 (1.6%)
17 (1.9%)
82 (9.2%) 311 (35.0%) 464 (52.3%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.4 continued
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Health Insurance
Perceived Severity Rating
1
2
3
No
55 (15.8%)
271 (77.7%)
23 (6.6%)
Yes
0 (0.0%)
1 (100.0%)
0 (0.0%)
Total
55 (15.7%)
272 (77.7%)
23 (6.6%
No
51 (16.2%)
235 (74.8%)
28 (8.9%)
Yes
0 (0.0%)
1 (100.0%)
0 (0.0%)
Total
51 (16.2%)
236 (74.9%)
28 (8.9%)
No
39 (17.7%)
163 (74.1%)
18 (8.2%)
Yes
0 (0.0%)
2 (66.7%)
1 (33.3%)
Total
39 (17.5%)
165 (74.0%
19 (8.5%)
No
145 (16.4%)
669 (75.8%)
69 (7.8%)
Yes
0 (0.0%)
4 (80.0%)
1 (20.0%)
Total
145 (16.3%)
673 (75.8%)
70 (7.9%)
Perceived Vulnerability Rating
1
2
3
4
5
No
5 (1.4%)
33 (9.5%) 171 (49.0%) 130 (37.2%)
10 (2.9%)
Yes
0 (0.0%)
0 (0.0%)
1 (100.0%)
0 (0.0%)
0 (0.0%)
Total
5 (1.4%)
33 (9.4%) 172 (49.1%) 130 (37.1%)
10 (2.9%)
No
2 (.6%)
29 (9.3%) 143 (45.7%) 128 (40.9%)
11 (3.5%)
Yes
0 (0.0%)
0 (0.0%)
1 (100.0%)
0 (0.0%)
0 (0.0%)
Total
2 (.6%)
29 (9.2%) 144 (45.9%) 128 (40.8%)
11 (3.5%)
No
0 (0.0%)
32 (14.5%)
99 (45.0%)
71 (32.3%)
18 (8.2%)
Yes
0 (0.0%)
1 (33.3%)
1 (33.3%)
1 (33.3%)
0 (0.0%)
Total
0 (0.0%)
33 (14.8%) 100 (44.8%)
72 (32.3%)
18 (8.1%)
No
7 (.8%)
94 (10.7%) 413 (46.8%) 329 (37.3%)
39 (4.4%)
Yes
0 (0.0%)
1 (20.0%)
3 (60.0%)
1 (20.0%)
0 (0.0%)
Total
7 (.8%)
95 (10.7%) 416 (46.9%) 330 (37.2%)
39 (4.4%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.5
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Retirement/Finances
Response Efficacy
1
2
3
4
5
No
24 (6.9%)
59 (17.0%) 105 (30.2%) 131 (37.6%)
29 (8.3%)
Yes
0 (0.0%)
0 (0.0%)
2 (100.0%)
0 (0.0%)
0 (0.0%)
Total
24 (6.9%)
59 (16.9%) 107 (30.6%) 131 (37.4%)
29 (8.3%)
No
21 (6.8%)
36 (11.7%)
92 (29.9%) 110 (35.7%)
49 (15.9%)
Yes
0 (0.0%)
1 (14.3%)
2 (28.6%)
4 (57.1%)
0 (0.0%)
Total
21 (6.7%)
37 (11.7%)
94 (29.8%) 114 (36.2%)
49 (15.6%)
No
26 (12.2%)
23 (10.8%)
72 (33.8%)
71 (33.3%)
21 (9.9%)
Yes
0 (0.0%)
0 (0.0%)
1 (10.0%)
8 (80.0%)
1 (10.0%)
Total
26 (11.7%)
23 (10.3%)
73 (32.7%)
79 (35.4%)
22 (9.9%)
No
71 (8.2%) 118 (13.6%) 269 (31.0%) 312 (35.9%)
99 (11.4%)
Yes
0 (0.0%)
1 (5.3%)
5 (26.3%)
12 (63.2%)
1 (5.3%)
Total
71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%)
Self-Efficacy Rating
1
2
3
4
5
No
4 (1.1%)
8 (2.3%)
32 (9.2%) 102 (29.3%) 202 (58.0%)
Yes
0 (0.0%)
0 (0.0%)
1 (50.0%)
1 (50.0%)
0 (0.0%)
Total
4 (1.1%)
8 (2.3%)
33 (9.4%) 103 (29.4%) 202 (57.7%)
No
6 (1.9%)
4 (1.3%)
22 (7.1%) 116 (37.7%) 160 (51.9%)
Yes
0 (0.0%)
1 (14.3%)
0 (0.0%)
1 (14.3%)
5 (71.4%)
Total
6 (1.9%)
5 (1.6%)
22 (7.0%) 117 (37.1%) 165 (52.4%)
No
4 (1.9%)
4 (1.9%)
27 (12.7%)
86 (40.4%)
92 (43.2%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
5 (50.0%)
5 (50.0%)
Total
4 (1.8%)
4 (1.8%)
27 (12.1%)
91 (40.8%)
97 (43.5%)
No
14 (1.6%)
16 (1.8%)
81 (9.3%) 304 (35.0%) 454 (52.2%)
Yes
0 (0.0%)
1 (5.3%)
1 (5.3%)
7 (36.8%)
10 (52.6%)
Total
14 (1.6%)
17 (1.9%)
82 (9.2%) 311 (35.0%) 464 (52.3%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.5 continued
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Retirement/Finances
Perceived Severity Rating
1
2
3
No
55 (15.8%)
270 (77.6%)
23 (6.6%)
0 (0.0%)
2 (100.0%)
0 (0.0%)
Yes
Total
55 (15.7%)
272 (77.7%)
23 (6.6%)
No
50 (16.2%)
232 (75.3%)
26 (8.4%)
1
(14.3%)
4
(57.1%)
2 (28.6%)
Yes
Total
51 (16.2%)
236 (74.9%)
28 (8.9%)
No
37 (17.4%)
158 (74.2%)
18 (8.5%)
2 (20.0%)
7 (70.0%)
1 (10.0%)
Yes
Total
39 (17.5%)
165 (74.0%)
19 (8.5%)
No
142 (16.3%)
660 (75.9%)
67 (7.7%)
3 (15.8%)
13 (68.4%)
3 (15.8%)
Yes
Total
145 (16.3%)
673 (75.8%)
70 (7.9%)
Perceived Vulnerability Rating
1
2
3
4
5
No
5 (1.4%)
33 (9.5%) 171 (49.1%) 129 (37.1%)
10 (2.9%)
0 (0.0%)
0 (0.0%)
1 (50.0%)
1 (50.0%)
0 (0.0%)
Yes
Total
5 (1.4%)
33 (9.4%) 172 (49.1%) 130 (37.1%)
10 (2.9%)
No
2 (.7%)
28 (9.1%) 144 (46.9%) 124 (40.4%)
9 (2.9%)
Yes
0 (0.0%)
1 (14.3%)
0 (0.0%)
4 (57.1%)
2 (28.6%)
Total
2 (.6%)
29 (9.2%) 144 (45.9%) 128 (40.8%)
11 (3.5%)
No
0 (0.0%)
31 (14.6%)
96 (45.1%)
71 (33.3%)
15 (7.0%)
Yes
0 (0.0%)
2 (20.0%)
4 (40.0%)
1 (10.0%)
3 (30.0%)
Total
0 (0.0%)
33 (14.8%) 100 (44.8%)
72 (32.3%)
18 (8.1%)
No
7 (.8%)
92 (10.6%) 411 (47.4%) 324 (37.3%)
34 (3.9%)
Yes
0 (0.0%)
3 (15.8%)
5 (26.3%)
6 (31.6%)
5 (26.3%)
Total
7 (.8%)
95 (10.7%) 416 (46.9%) 330 (37.2%)
39 (4.4%)

70

Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.6
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Advance Planning
Response Efficacy
1
2
3
4
5
No
24 (6.9%)
59 (17.1%) 107 (30.9%) 129 (37.3%)
27 (7.8%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
2 (50.0%)
2 (50.0%)
Total
24 (6.9%)
59 (16.9%) 107 (30.6%) 131 (37.4%)
29 (8.3%)
No
21(6.8%)
37 (12.0%)
94 (30.5%) 111 (36.0%)
45 (14.6%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
3 (42.9%)
4 (57.1%)
Total
21 (6.7%)
37 (11.7%)
94 (29.8%) 114 (36.2%)
49 (15.6%)
No
26 (12.7%)
22 (10.7%)
69 (33.7%)
68 (33.2%)
20 (9.8%)
Yes
0 (0.0%)
1 (5.6%)
4 (22.2%)
11 (61.1%)
2 (11.1%)
Total
26 (11.7%)
23 (10.3%)
73 (32.7%)
79 (35.4%)
22 (9.9%)
No
71 (8.3%) 118 (13.7%) 270 (31.4%) 308 (35.9%)
92 (10.7%)
Yes
0 (0.0%)
1 (3.4%)
4 (13.8%)
16 (55.2%)
8 (27.6%)
Total
71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%)
Self-Efficacy Rating
1
2
3
4
5
No
4 (1.2%)
8 (2.3%)
33 (9.5%) 101 (29.2%) 200 (57.8%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
2 (50.0%)
2 (50.0%)
Total
4 (1.1%)
8 (2.3%)
33 (9.4%) 103 (29.4%) 202 (57.7%)
No
6 (1.9%)
5 (1.6%)
22 (7.1%) 115 (37.3%) 160 (51.9%)
Yes
0 (0.0%)
0 (0.0%)
0 (0.0%)
2 (28.6%)
5 (71.4%)
Total
6 (1.9%)
5 (1.6%)
22 (7.0%) 117 (37.1%) 165 (52.4%)
No
4 (2.0%)
4 (2.0%)
23 (11.2%)
84 (41.0%)
90 (43.9%)
Yes
0 (0.0%)
0 (0.0%)
4 (22.2%)
7 (38.9%)
7 (38.9%)
Total
4 (1.8%)
4 (1.8%)
27 (12.1%)
91 (40.8%)
97 (43.5%)
No
14 (1.6%)
17 (2.0%)
78 (9.1%) 300 (34.9%) 450 (52.4%)
Yes
0 (0.0%)
0 (0.0%)
4 (13.8%)
11 (37.9%)
14 (48.3%)
Total
14 (1.6%)
17 (1.9%)
82 (9.2%) 311 (35.0%) 464 (52.3%)
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Total

60+

40-59

19-39

Total

60+

40-59

19-39

Table 4.6 continued
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes
to Advance Planning
Perceived Severity Rating
1
2
3
No
55 (15.9%)
268 (77.5%)
23 (6.6%)
Yes
0 (0.0%)
4 (100.0%)
0 (0.0%)
Total
55(15.7%)
272 (77.7%)
23 (6.6%)
No
50 (16.2%)
234 (76.0%)
24 (7.8%)
Yes
1 (14.3%)
2 (28.6%)
4 (57.1%)
Total
51 (16.2%)
236 (74.9%)
28 (8.9%)
No
37 (18.0%)
151 (73.7%)
17 (8.3%)
Yes
2 (11.1%)
14 (77.8%)
2 (11.1%)
Total
39 (17.5%)
165 (74.0%)
19 (8.5%)
No
142 (16.5%)
653 (76.0%)
64 (7.5%)
Yes
3 (10.3%)
20 (69.0%)
6 (20.7%)
Total
145 (16.3%)
673 (75.8%)
70 (7.9%)
Perceived Vulnerability Rating
1
2
3
4
5
No
5 (1.4%)
32 (9.2%) 171 (49.4%) 128 (37.0%)
10 (2.9%)
0 (0.0%)
1 (25.0%)
1 (25.0%)
2 (50.0%)
0 (0.0%)
Yes
Total
5 (1.4%)
33 (9.4%) 172 (49.1%) 130 (37.1%)
10 (2.9%)
No
2 (.7%)
28 (9.1%) 142 (46.3%) 125 (40.7%)
10 (3.3%)
0 (0.0%)
1 (14.3%)
2 (28.6%)
3 (42.9%)
1 (14.3%)
Yes
Total
2 (.6%)
29 (9.2%) 144 (45.9%) 128 (40.8%)
11 (3.5%)
No
0 (0.0%)
33 (16.1%)
91 (44.4%)
68 (33.2%)
13 (6.3%)
0 (0.0%)
0 (0.0%)
9 (50.0%)
4 (22.2%)
5 (27.8%)
Yes
Total
0 (0.0%)
33 (14.8%) 100 (44.8%)
72 (32.3%)
18 (8.1%)
No
7 (.8%)
93 (10.8%) 404 (47.1%) 321 (37.4%)
33 (3.8%)
0 (0.0%)
2 (6.9%)
12 (41.4%)
9 (31.0%)
6 (20.7%)
Yes
Total
7 (.8%)
95 (10.7%) 416 (46.9%) 330 (37.2%)
39 (4.4%)
Discussion
The analyses conducted sought to better understand several interpersonal and
economic behaviors of people following the receipt of DTC PGT results. We were able to
use age groups and the concepts of the PMT to analyze the respondents’ decisions to
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disclose their testing results to others, change health insurance, change financial and
retirement plans, and change advance planning behaviors. The small size of those
participants who engaged in the behaviors of interest limited the use of statistical analysis
methods, and thus there are no statements of statistical significance among the
contingency tables (Tables 4.3-4.6). Analyses of these numbers instead focuses on the
ratings of the four PMT concept measures as they differ among the age groups and the
differences between those who did and did not engage in the behavior.
These measures of the PMT concepts show some of the trends that are associated
with taking or not taking the actions of interest and are important for the future of DTC
PGT in the context of society and healthcare. As genomic level knowledge permeates
society, more people will be armed with a large amount of information that may lead
them to engage in any of these actions. Understanding these trends helps to better
understand the influence that participant perceptions of self-efficacy, response efficacy,
risk, and vulnerability have over these four results utilization behaviors.
In examining the sharing of DTC PGT results with another person, those who did
share tended to have higher self-efficacy and response efficacy ratings. A majority of
those who shared their DTC PGT results had moderate perceived severity ratings and
moderate to higher perceived vulnerability ratings. When examining trends among the
age groups the patterns of ratings among those who did share their results mirror the
overall patterns. Greater than 80% of those who shared had high self-efficacy ratings in
each of the three age groups and in the overall sample. The perceived vulnerability
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ratings were higher among the 60+ group who shared their results than those who shared
in the other two age groups.
More people did share their results from the DTC PGT than those who did not,
this may suggest that they are seeking out the opinions of others (eg, family members,
healthcare providers) regarding their results. In light of the increased perceived
vulnerability scores, the opinions sought could range from seeking other’s views on DTC
PGT in general to dealing with specific results and many other possible perspectives of
the results (McBride et al., 2010).
In examining the use of the DTC PGT results to make changes in insurance, a
very low number of events prohibits making strong statements about these participants,
though broadly across all age groups it is evident that moderate perceived severity and
perceived vulnerability along with higher response efficacy and self-efficacy ratings were
more common among those who did make changes to their insurance in response to
receiving their DTC PGT results.
Those who made changes to their retirement and financial plans in response to
receiving DTC PGT results were more likely to have moderate to higher response
efficacy ratings, higher self-efficacy ratings, moderate perceived severity, and moderate
to higher perceived vulnerability ratings. Across the age groups these were very similar,
though the 19-39 group members who made changes were likely to have more moderate
self-efficacy and response efficacy results than the other two age groups.
The overall trends of those who made changes to their advance directives are the
same as those who made changes to retirement and financial plans. In both cases, the
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majority of those participants who made changes were members of the 60+ group, though
much more in the retirement changes than any other behavior. Those in the 60+ group
who made changes to their retirement were more likely to have moderate to higher
response efficacy ratings compared to the other two age groups where those who changed
had high response efficacy ratings.
In the application of the PMT, Rogers (1983) identifies perceived vulnerability
and perceived severity as contributing to the fear appeal that contributes to the drive to
make changes in behavior. The findings related to these two significant measures in the
four tables both support and contradict that statement. Those who had a higher perceived
vulnerability are more likely to engage in the practice of sharing their DTC PGT
results—the target behavior thus supporting the value of fear appeals. However, the lack
of differentiation among those who did make changes to retirement by type of changes
(eg. adding money, removing money, increasing deductions) makes it difficult to
determine if the behaviors related to a moderate perceived severity are consistent with
Rogers’ thoughts about PMT (1983). The findings of this study are similar to others in
noting a paradox in the perceived vulnerability and perceived severity scores and their
influence on the behaviors of interest (Cismaru & Lavack, 2007). The fear of negative
consequences can only be examined through the lens of the participant’s evaluation of the
severity of the consequences (Rogers, 1983).
Age group differences in engagement in the target behaviors may be related to
situational aspects of the age groups. The 60+ group made up the largest portion of
those who made changes in advance directives in response to their DTC PGT results,
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which may speak to a perception among this age group of increased proximity of agerelated decline or later-life disease processes. This older age group may view their results
as fatalistic and seek to be proactive in addressing the possibility of a negative outcome
related to genetic disease. Research has shown that 60+ year olds are more likely to have
an advance directive in place than other age groups (Rao, Anderson, Lin, Laux, 2014).
The findings of this study indicate an early indication that the PMT may be a
valuable tool in the evaluation of decisions made in response to DTC PGT results, an area
that had not been previously studied using PMT. Additionally, the concepts of the PMT
are key as they support the importance of the DTC PGT consumers’ perceptions in their
processing the results delivered by the service they used (Kaufman et al., 2012; McBride
et al., 2010).
Limitations
The PGen data set provides a robust study design with a large sample of
participants; however, there are limitations to the use of the data in this study. The
sample is not as diverse as society, and is made up of mostly white, married females.
Self-selection bias is also a concern for this data set as the respondents opted into the
study after initiating DTC PGT. Additionally, the non-controlled design of the PGen
study cannot support any conclusions related causal relationships. The small sample of
events of interest is one large limitation on the analysis, and while this analysis addresses
trends in ratings among age groups in those who did engage in the target events it does
not offer statistical evaluations of significance because of the limited sample size. The
findings in this article are specifically about DTC PGT participants’ behaviors, but they
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may offer some insight into trends that may also be present in clinical genetic testing
populations. Further examination of the PMT as a model for the evaluation and study of
DTC PGT results utilization behaviors and determining whether these trends exist outside
of the study sample will require further studies in more diverse populations.
Conclusions
The relationships among age, the PMT concepts, and insurance, financial,
retirement, advance directive and results disclosure behaviors of DTC PGT participants
are multifaceted. Evaluation of the concepts in the PMT appears to aid in better
understanding the actions that DTC PGT consumers take in response to their results. In
addition to the perceptions included in the PMT concepts, the influence of age group
membership must also be acknowledged as a difference in those who engaged in
retirement and advance planning change behaviors; further study would be valuable in
offering a deeper assessment of these age group differences. Also, further study will be
valuable to evaluate the PMT concepts in genetic decision-making outside of the DTC
PGT context. Subsequent studies—quantitative and qualitative—are needed to help
better understand how DTC PGT companies and healthcare providers can best support
the educational and decision-making needs of all those who engage in DTC PGT. A
larger study with a larger sample of DTC PGT result utilization behavior events is key in
understanding the role of the PMT in explaining these behaviors. In addition, there is a
need to acknowledge the policy implications that these behaviors may have, while these
tests are not necessarily entered into the medical record, they are influencing the
consumer behaviors of the result recipients (Kaufman et al., 2012; McBride et al, 2009,
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2010). Policy makers must seek to find balance in protecting commercial and consumer
interests as they address the new frontiers of consumer-driven health services.
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CHAPTER FIVE
CONCLUSION
This dissertation set out to increase the state of understanding of the beliefs,
knowledge, and perceptions of older adults related to genetics and genomics. Studies of
decision-making related to engaging in genomic testing and utilization of the genomic
testing results were conducted. In order to better describe older adults, the study
compared the differences and similarities in measures over time and among three age
groups, 19-39 year olds, 40-59 year olds, and 60+ year olds. The focus was on older
adults in order to strengthen the current knowledge and add new findings to provide a
foundation for further study to be able to move toward more individualized approaches
informed by the similarities and differences of the age groups.
The three manuscripts included in this dissertation approach the area of genetic
and genomic testing and decision-making from unique angles. The manuscripts attempt
not only to describe the various concepts, measures, and behaviors of interest by age
group but also to contextualize them within genetics and genomics. Combined, the
manuscripts help to frame genetic and genomic information and decision-making across
age groups to build on past studies in genetics, genomics, decision-making, and older
adults.
Overview of Manuscripts
The first manuscript examines several concepts of behavioral economics,
exploring the possibilities of applying the behavioral economic concepts in decisionmaking support related to genomics. Written as a general overview of the concepts for a
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naïve audience of healthcare providers and researchers, the first manuscript provides
specific situations where the concepts may be of value in clinical practice. Several
concepts of behavioral economics prove to be valuable ways to explore decision-making
and decision-support in the area of genomics. While these concepts have value, genomic
testing and information stimulates emotions that may move beyond the realm of
behavioral economic perspectives. Individual contexts are an important part of the
application of behavioral economics. This manuscript is on the leading edge of genomics
and behavioral economics, and this area of study shows promise for future development.
The second manuscript utilizes a secondary analysis of the Impact of Personal
Genomics (PGen) data set to examine age group differences in knowledge, perspectives,
and beliefs related to genetics and genomics, genetic testing and results. The article
examines differences among the age groups in five specific areas: genetic knowledge,
self-rated genetic competency, beliefs about personal utility of genetics, response efficacy
of genetics, and influencers and reasons for engaging in direct-to-consumer personal
genomic testing (DTC PGT). This article identifies several differences over time and
among age groups related to these measures that provide insight into the age groups and
general trends as they change over time. One overall pattern of note is that from initial
evaluation to the six month follow-up evaluation the mean values for self-rated genetic
competency, personal utility of genetics, and genetic response efficacy all decreased
significantly, which may suggest that over time and exposure to the DTC PGT results the
participants felt less confident in themselves, the testing, and the usefulness of the results.
Age group differences were significant among the 60+ group in genetic knowledge and
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personal utility of genetics. These may be areas where the 60+ population may benefit
from increased support when engaging in genetic decision-making or genetic testing in
general. Factor analysis of 19 items that evaluated participants’ influences and motives
for engaging in DTC PGT identified two unique factors for the overall population,
‘Health and Future’ and ‘Curiosity and Intrigue.’ Age group membership was a
significant contributor to variance of mean scores of the ‘Health and Future’ factor with
the 60+ group having a significantly lower mean score than the other two age groups.
This manuscript is written with the intent to further examine differences noted among age
groups in previous studies on genetic knowledge, and examine any differences in the
other areas in order to build a new and better understanding of age group differences
related to decision-making, genetics and genomics, and testing and results.
The third manuscript also utilizes a secondary analysis of the PGen data set as it
explores the use of the Protection Motivation Theory (PMT) as a framework for better
understanding reaction-behaviors of DTC PGT consumers in response to their results.
The four specific reaction-behaviors of interest included: 1) disclosing of the DTC PGT
results to someone else, 2) making changes to health insurance, 3) making changes to
retirement and financial plans, and 4) making changes to advance planning. In addition
to the concepts of the PMT, age group membership was included in the exploration of the
behaviors. The findings of the study support the application of the PMT to DTC PGT
consumer behaviors. Higher levels of response efficacy and self-efficacy were noted to
be present in those who engaged in the studied behaviors following DTC PGT result
receipt. This manuscript offers a novel area of application of the PMT in genetics and has
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the possibility to inform future study and policy as the fields of genetic testing and DTC
PGT continue to develop. The application of the PMT to these behaviors also supports
the use of this model in further studies of decision-making in DTC PGT and clinical
genetic testing populations.
Limitations and Gaps
Each of the three manuscripts has strengths and weaknesses. This dissertation
includes one literature-based manuscript and two secondary data analysis-based
manuscripts. The literature-based manuscript must be evaluated in light of the fact that
there is currently limited research addressing the relationship between genetics and
behavioral economic concepts. Genetic decision-making also has a limited research
literature base. The aim of the manuscript is to examine both fields and explore the areas
where overlap exists with potential as new areas for research.
While the PGen study was well designed, provided a vast amount of information
about the participants, and evaluated a variety of concepts, limitations still exist. The
findings in the two data-based manuscripts in this dissertation are limited in that they rely
heavily on data collected by other scientists among a population that is less diverse than
the general population related to a lack of diversity in ethnicity, educational attainment,
and income distribution. There is inherent selection bias in the self-referral design used
via the online survey service and randomization to provide a control group to strengthen
comparisons was not feasible. Age grouping of the data also has limitations as there are
numerous differences among age groups that may influence participation and even
accuracy of the survey program. Additionally, the differences among those members in
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the 60+ age group must be acknowledged as the life changes that occur after 60 years of
age create a greater diversity among this age group than the age grouping may suggest. It
is also important to acknowledge the very different circumstances that may surround
clinical genetic testing which may not be present when the participants engaged in DTC
PGT. The underlying nature of the genetic information does, however, create a common
thread between DTC PGT results and clinical genetic or genomic testing.
Even with limitations, the PGen data does provide valuable initial glimpses of
how individuals engage with decision-making and results utilization related to geneticlevel knowledge. The dissertation work does have a few gaps, since it does not provide
direct insight into the clinical genetics area. While using behavioral economics as an
initial point of exploration, due to the secondary analysis design, the analysis could not be
designed to test behavioral economics concepts directly. There are also some challenges
in the direct translation of the behavioral economics and genetics findings into practice.
There must be decision-making support and at the same time the limitation or alleviation
of any perceived or actual coercion in the support provided.
In addition, the age-related differences described in this dissertation may change
as generations of people with more exposure to the science of genetics and genetic testing
age. This may mean that older adults may still have differences, but the knowledge-based
measures may vary. Though it should be noted that as the age-knowledge difference may
narrow, it is highly unlikely that the differences in genetic knowledge associated with age
will be eliminated entirely as advances in genetics continue to be made. Additionally, the
low number of events related to results utilization is a limitation in making any broad
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generalizations to these behaviors—though it may offer important insight for the design
of future research.
Discussion and Recommendations
In looking at the three manuscripts individually and as a collective work, it is
apparent that the area of genetic decision-making is complex and still in the early stages
of understanding. There is currently a limited foundation on which one can build a
universal approach to making these decisions because of the unique nature of the genetic
information that is provided through testing. The findings from these manuscripts may
not be fully generalizable to the clinical testing experience; however, they do provide
some insights into age group similarities and differences in trends, behaviors, and
influences of genetic decision-making processes. Those insights may add to other
research in the field to influence the design and implementation of clinical genetics
studies or trials that address decision-making, decision aides and other interventions.
There are clear differences in the older adult population, and these differences
support the need for unique approaches especially in the area of genetics. As suggested
previously, the results of the second and third manuscripts have limited generalization
potential. These findings need to be evaluated in more diverse populations and clinical
testing situations to see if the findings are similar to those presented here.
The PMT has been applied in various aspects of genetics, but this is the first time
where PMT has been applied to decision-making related to the utilization and disclosure
of DTC PGT results, and genetic test results in general (Azzarello et al., 2006; Fisher et
al., 2012; Helmes 2002; Ralph et al., 2014; Vadaparampil et al. 2004; Wright et al.,
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2006). Additionally, the PMT constructs may be helpful in designing and testing
decision-making tools and interventions to support the decision-making process.
This work has implications for practice, education, and policy, as it brings new
findings and perspectives to the study of genomics and gerontology. In the realm of
practice, the work of this dissertation can help increase the awareness of the context of
decision-making related to healthcare and genetics (Bayliss et al, 2014; Operskalski &
Barbey, 2016). Understanding that while shared decision-making and other tactics are in
existence, the individual realities of the patients who are making the decisions must also
be taken into account. Health care practice is moving toward an even more personalized
approach as patient satisfaction and customer service become hallmarks of the industry
that used to coast on “doctor knows best” paternalism (Drolet & White, 2012). In this
new approach to healthcare, professionals must be informed about the range of contextual
factors that influence the actions and desires of patients. In addition to the concepts of the
PMT, the application of behavioral economic approaches to supporting decision-making
in genetics may offer a good starting place.
As for educational implications, this work is helpful in further defining the unique
needs of older adult populations specifically in genetic decision-making. Healthcare
providers and researchers need to be educated about and encouraged to understand these
needs and differences among age groups. The ability of the PMT to be applied in
predicting behaviors after receipt of DTC PGT results further supports a need for holistic
approaches to patient care. Healthcare providers should be trained to engage patients and
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understand their individual perspectives and beliefs when engaging in genetic testing
decision-making and discussing health behavior changes.
The growing areas of DTC PGT, clinical genetics, and genetic science in general
continue to push the bounds of extant policy (McBride et al., 2010). While GINA and
other policies that address genetic discrimination exist now to protect the rights of the
individual to access the latest technologies available without fear of retribution, these
policies will need to be revisited often in order to address new areas of concern as they
develop (Green et al., 2015). The reactive behaviors of the DTC PGT participants are one
example of a possible new area where policy intervention may be needed. When policies
are developed to address these areas, it is imperative to protect both citizen interests and
private interests. In the absence of a dual protection, provision of services may become
too expensive or risky for the private entities, or access to genetic information may
become too risky for citizens who may fear punitive actions from private entities based
on the possibility of future disease.
Synthesis
Each of the three manuscripts approached the topic of genetics, genomics, and
decision-making in a unique way, and, at the same time, the three manuscripts are
complementary to each other. The behavioral economics and genomics manuscript uses
an integrative review approach to evaluate the applicability of behavioral economics to
genomics. As has been previously discussed, the behavioral economic approaches to
decision-making do not rely solely on the emotions of decision makers (Lerner, Li,
Valdesolo, & Kassam, 2015). The behavioral economic approaches to describing
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decision-making behaviors also include some perspective and perception-related concepts
(Ariely, 2009).
Some of the behavioral economic concepts are carried over into the second
manuscript, in order to assist in contextualizing the decision-making processes. The
analysis utilizes multiple measures to describe different aspects of the context of the
decisions related to engaging in DTC PGT, and examines them over time. The factor
analysis of the influencers and motives behind the choice to engage in DTC PGT also
aids in the contextualization of the decision-making process. The evaluation of
knowledge, perceptions, beliefs, and the two main factors influencing DTC PGT
participation across age groups adds another layer of analysis. These three areas of
analysis work in conjunction to further describe the contexts in which these decisions are
made across age groups.
The third manuscript’s analysis of the DTC PGT results utilization provides
additional contextualization as the PMT proves to be a valuable tool in better
understanding reaction-behaviors following results receipt. The four concepts of the PMT
(perceived vulnerability, perceived severity, response efficacy, and self-efficacy)
incorporate perspectives of the decision makers and aid in understanding some of the
driving forces of the decision-making in DTC PGT consumers. The 40-59 and 60+
groups were the largest groups that made changes in insurance or finances or advance
directives in response to their DTC PGT results.
The three manuscripts follow a logical progression moving from the application
of the behavioral economic approaches and concepts to genomic decision-making, to the
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evaluation of contextual factors as they influence DTC PGT engagement, and finally in
examining the PMT, a model that incorporates some of the contextual factors, as a viable
tool for studying DTC PGT results utilization. In addition to the progressive focus on
context and perspective as important factors in genomic testing, these manuscripts also
seek to examine the age-related differences in engagement in DTC PGT and the
utilization of the results. Age is an important part of the contexts of decision-making.
From a behavioral economics perspective, with increasing age the number of experiences
for a person to draw on in decision-making also increases. Also, older adults may have
very different perspectives and motives as a result of their advancing age. Their focus
may be less future-oriented than other age groups.
Progressing from behavioral economics to the application of PMT in DTC PGT,
these three manuscripts address the interface of genetics, genomics, and older adults with
a specific focus on decision-making. This work further supports the limited existing
literature that identifies differences in the genetic knowledge of older adults when
compared to other age groups (Ashida et al. 2011; Carere et al. 2015; Morren et al, 2007).
The findings in the manuscripts also build on the existing literature and expand that
knowledge by examining behavioral economics as a lens for examining genomic
decision-making, the context of engaging in DTC PGT, the age group differences in
measures of genetic personal utility, self-rated genetic competency, and response
efficacy, and PMT as a framework for studying genomic decision-making in response to
DTC PGT results.
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In addition to the areas where study has been expanded, several findings have the
potential to shape future study. The findings from the third manuscript support the use of
the PMT as a model on which to base further study of DTC PGT decision-making. As of
the writing of this dissertation, PMT had never been used to study DTC PGT decisionmaking nor had it been applied to insurance, retirement, finance, or advance directive
decision-making as a result of genetic testing. The findings related to age group
differences may be useful in the design and study of personalized approaches in DTC
PGT and possibly even clinical genetics. These differences could have implications for
the study of decision-making, patient education, and results utilization in numerous
contexts within genetics and healthcare.
This dissertation addresses a growing area of concern as genetic information is
becoming a consumer-driven commodity. The field requires further exploration with this
work beginning to address some key areas of the field of healthcare genetics, specifically
ethics and policy as well as decision-science. The ethical and policy aspects of the work
included within this dissertation span genetics and aging. There is a need for further
study of the implications of genetic testing and decision-making over a broader and more
diverse group of tested individuals. This work presents the study and identification of
some age group differences that may be important in informing policy as the field of
genetics changes. Decision-making and decision support in DTC PGT and clinical
genetics are areas that continue to need support in research and practice. The
understanding of the decision-making processes and contexts is an important part of
ethical and professional responsibility in the use and application of genetic testing.
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Decision science is also a key part of the innovation in this dissertation as it
applies the PMT in new areas: DTC PGT, and making changes to health insurance,
financial and retirement plans, and advance directives. The dissertation also provides
further description of the different beliefs, perspectives, and knowledge related to
genetics and genetic testing which are essential in the study of healthcare genetics.
Future Directions
This dissertation research has created a variety of opportunities for next steps both
to build on this research and to translate the findings to inform or change practice,
education, and policy. The findings identified in the three manuscripts of the dissertation
will be useful in the design and implementation of studies in the clinical genetic testing
environment. The designs of these studies may vary from the use of a hypothetical
scenario in evaluating decision-making behavior to the use of a similar type of survey
evaluating the behavioral economic, PMT, and aging concepts in a clinical genetic testing
environment. Examination of the concepts in a more diverse population will also be a
logical next step in expanding this work. Another area of future work is the translation
of the findings into designs of novel decision support interventions or decision-making
aids for clinical practice that allow for generalized support with individualization based
on the patients’ unique decision-making context. These different areas may be addressed
individually or may be combined in several ways.
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APPENDIX A
DESCRIPTIVE STATISTICS FOR ALL IMPACT OF PERSONAL GENOMICS
STUDY ITEMS INCLUDED IN DISSERTATION ANALYSES
Table A.1
Item-wise Analysis for Genetic Knowledge Scale by Age Group at Baseline and 6
Month Follow-up
Item (Correct Answer)
Group
Baseline
6 Month
19-39 years old 99.1 (347) 99.7 (349)
Healthy parents can have a child with
40-59 years old 99.7 (314) 99.0 (312)
an inherited disease (T)
60+ years old
99.1 (221) 98.2 (219)
Overall
99.3 (882) 99.1 (880)
19-39 years old 96.3 (337) 95.7 (335)
If your close relatives have diabetes or
40-59 years old 96.5 (304) 96.2 (303)
heart disease, you are more likely to
60+ years old
93.3 (208) 96.0 (214)
develop these conditions (T)
Overall
95.6 (849) 95.9 (852)
19-39 years old 99.4 (348) 99.4 (348)
Some genetic disorders occur more
40-59 years old 99.0 (312) 99.4 (313)
often within particular ethnic groups
60+ years old
99.6 (222) 99.1 (221)
(T)
Overall
99.3 (882) 99.3 (882)
19-39 years old 65.4 (229) 67.1 (235)
Most genetic disorders are caused by
40-59 years old 61.9 (195) 66.7 (210)
only a single gene (F)
60+ years old
65.0 (145) 71.3 (159)
Overall
64.1 (569) 68.0 (604)
19-39 years old 87.4 (306) 86.9 (304)
Once a genetic marker for a disorder is
40-59 years old 87.9 (277) 91.7 (289)
identified in a person, the disorder can
60+ years old
85.2 (190) 86.1 (192)
usually be prevented or cured (F)
Overall
87.0 (773) 88.4 (785)
19-39 years old 90.9 (318) 91.7 (321)
A disease is only genetically
40-59 years old 89.2 (281) 87.6 (276)
determined if more than one family
60+ years old
84.8 (189) 82.5 (184)
member is affected (F)
Overall
88.7 (788) 88.0 (781)
19-39 years old 96.0 (336) 98.9 (346)
Some of the genetic disorders occur
40-59 years old 92.1 (290) 94.9 (299)
later in adult life (T)
60+ years old
91.5 (204) 90.1 (201)
Overall
93.5 (830) 95.3 (846)
A healthy lifestyle can prevent or lessen 19-39 years old 97.4 (341) 99.4 (348)
the negative consequences of having
40-59 years old 97.1 (306) 97.5 (307)
genetic predispositions to some
60+ years old
92.4 (206) 96.9 (216)
diseases (T)
Overall
96.1 (853) 98.1 (871)
19-39 years old 96.0 (336) 97.7 (342)
The environment has little or no effect
40-59 years old 94.6 (298) 93.7 (295)
on how genes contribute to disease (F)
60+ years old
90.1 (201) 89.2 (198)
Overall
94.0 (835) 94.1 (835)
Note: Values represent % (n).
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Table A.2
Item-wise Analysis for Self-Rated Genetic Competency Scale at Baseline Survey
Item
Group
SDA
DA
SWDA
N
SWA
A
SA
Mean(SD)
I am confident in my ability to understand information about genetics.
19-39 years old
2.0 (7)
0.6 (2)
3.7 (13)
3.7 (13)
12.0 (42) 34.3 (120) 43.7 (153)
6.01 (1.279)
40-59 years old
1.9 (6)
0.3 (1)
1.0 (3)
3.2 (10)
12.4 (39) 35.6 (112) 45.7 (144)
6.13 (1.143)
60+ years old
1.3 (3)
0.0 (0)
0.9 (2)
4.5 (10)
15.7 (35) 38.1 (85)
39.5 (88)
6.05 (1.072)
Overall
1.8 (16)
0.3 (3)
2.0 (18)
3.7 (33) 13.1 (116) 35.7 (317 43.4 (385)
6.06 (1.182)
I am able to understand information about how genes can affect my health.
19-39 years old
1.7 (6) 0.0 (0)
2.3 (8)
3.1 (11)
12.9 (45) 34.3 (120) 45.7 (160)
6.11 (1.156)
40-59 years old
1.9 (6) 0.0 (0)
1.0 (3)
2.2 (7)
10.8 (34) 38.7 (122) 45.4 (143)
6.18 (1.089)
60+ years old
0.9 (2) 0.0 (0)
0.4 (1)
0.9 (2)
13.9 (31) 42.6 (95)
41.3 (92)
6.20 (.904)
Overall
1.6 (14) 0.0 (0)
1.4 (12)
2.3 (20) 12.4 (110) 38.0 (337) 44.5 (395)
6.16 (1.073)
I have a good idea about how genetics may influence risk for disease generally.
19-39 years old
1.4 (5)
1.4 (5)
2.0 (7)
4.3 (15)
18.3 (64) 35.1 (123) 37.4 (131)
5.92 (1.221)
40-59 years old
2.2 (7)
0.6 (2)
1.9 (6)
4.1 (13)
16.2 (51) 38.7 (122) 36.2 (114)
5.92 (1.231)
60+ years old
0.9 (2)
1.3 (3)
0.0 (0)
4.5 (10)
18.4 (41) 44.4 (99)
30.5 (68)
5.93 (1.053)
Overall
1.6 (14) 1.1 (10)
1.5 (13)
4.3 (38) 17.6 (156) 38.7 (344) 35.2 (313)
5.92 (1.184)
I have a good idea about how my own genetic make-up might affect my risk for disease.
19-39 years old
2.3 (8)
2.3 (8)
5.7 (20)
6.6 (23)
20.9 (73) 31.7 (111) 30.6 (107)
5.59 (1.437)
40-59 years old
1.9 (6)
2.2 (7)
3.2 (10)
9.2 (29)
18.1 (57) 35.2 (111)
30.2 (95)
5.66 (1.363)
60+ years old
0.9 (2)
2.2 (5)
1.8 (4)
7.6 (17)
18.8 (42) 43.0 (96)
25.6 (57)
5.73 (1.194)
Overall
1.8 (16) 2.3 (20)
3.8 (34)
7.8 (69) 19.4 (172) 35.8 (318) 29.3 (259)
5.65 (1.353)
I am able to explain to others how genes affect one’s health.
19-39 years old
2.3 (8) 3.1 (11)
6.3 (22)
8.9 (31)
25.4 (89) 28.3 (99)
25.7 (90)
5.40 (1.466)
40-59 years old 3.5 (11)
1.3 (4)
6.0 (19)
9.8 (31)
28.3 (89) 25.4 (80)
25.7 (81)
5.37 (1.471)
60+ years old
1.3 (3)
3.1 (7)
5.4 (12)
18.4 (41)
28.7 (64) 25.6 (57)
17.5 (39)
5.17 (1.354)
Overall
2.5 (22) 2.5 (22)
6.0 (53) 11.6 (103) 27.3 (242) 26.6 (236) 23.6 (210)
5.33 (1.442)
Note: SDA=Strongly Disagree; DA=Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; A=Agree;
SA=Strongly Agree.
Values Represent: %(n)
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Table A.3
Item-wise Analysis for Self-Rated Genetic Competency Scale at 6 Month Follow-up Survey
Item
Group
SDA
DA
SWDA
N
SWA
A
SA
Mean(SD)
I am confident in my ability to understand information about genetics.
19-39 years old
0.9 (3)
2.3 (8) 4.3 (15)
4.9 (17)
20.0 (70) 40.9 (143)
26.9 (94) 5.71 (1.244)
40-59 years old
1.6 (5)
0.0 (0) 4.1 (13)
4.1 (13)
27.3 (86) 36.8 (116)
26.0 (82) 5.70 (1.176)
60+ years old
1.3 (3)
3.6 (8) 4.5 (10)
11.2 (25)
24.2 (54)
40.4 (90)
14.8 (33) 5.34 (1.311)
Overall
1.2 (11) 1.8 (16) 4.3 (38)
6.2 (55)
23.6 (210) 39.3 (349) 23.5 (209) 5.61 (1.247)
I am able to understand information about how genes can affect my health.
19-39 years old
0.9 (3)
1.4 (5)
2.3 (8)
5.1 (18)
24.0 (84) 38.6 (135)
27.7 (97) 5.77 (1.149)
40-59 years old
1.6 (5)
0.3 (1)
2.5 (8)
3.2 (10)
28.6 (90) 36.2 (114)
27.6 (87) 5.76 (1.145)
60+ years old
0.9 (2)
0.9 (2)
3.1 (7)
4.9 (11)
26.5 (59) 47.5 (106)
16.1 (36) 5.62 (1.066)
Overall
1.1 (10)
0.9 (8) 2.6 (23)
4.4 (39)
26.2 (233) 40.0 (355) 24.8 (220) 5.73 (1.128)
I have a good idea about how genetics may influence risk for disease generally.
19-39 years old
0.9 (3)
0.6 (2) 3.1 (11)
4.0 (14)
24.0 (84) 39.7 (139)
27.7 (97) 5.80 (1.108)
40-59 years old
1.6 (5)
0.6 (2)
1.6 (5)
5.7 (18)
26.3 (83) 39.0 (123)
25.1 (79) 5.72 (1.145)
60+ years old
0.9 (2)
0.9 (2)
2.2 (5)
5.8 (13)
31.8 (71)
42.6 (95)
15.7 (35) 5.57 (1.050)
Overall
1.1 (10)
0.7 (6) 2.4 (21)
5.1 (45)
26.8 (238) 40.2 (357) 23.8 (211) 5.71 (1.109)
I have a good idea about how my own genetic make-up might affect my risk for disease.
19-39 years old
0.9 (3)
1.1 (4) 3.4 (12)
3.4 (12)
29.7 (104) 39.1 (137)
22.3 (78) 5.67 (1.120)
40-59 years old
1.6 (5)
1.0 (3)
1.6 (5)
3.8 (12)
29.8 (94) 39.4 (124)
22.9 (72) 5.69 (1.131)
60+ years old
0.4 (1)
0.9 (2)
2.7 (6)
5.8 (13)
29.1 (65) 47.5 (106)
13.5 (30)
5.59 (.996)
Overall
1.0 (9)
1.0 (9) 2.6 (23)
4.2 (37)
29.6 (263) 41.3 (367) 20.3 (180) 5.65 (1.094)
I am able to explain to others how genes affect one’s health.
19-39 years old
1.7 (6) 4.0 (14) 7.4 (26)
9.7 (34)
30.9 (108)
25.7 (90)
20.6 (72) 5.23 (1.435)
40-59 years old
2.9 (9)
2.5 (8) 9.2 (29)
10.2 (32)
37.1 (117)
22.2 (70)
15.9 (50) 5.06 (1.420)
60+ years old
4.0 (9) 5.8 (13) 9.4 (21)
18.8 (42)
34.1 (76)
19.3 (43)
8.5 (19) 4.65 (1.468)
Overall
2.7 (24) 3.9 (35) 8.6 (76) 12.2 (108)
33.9 (301) 22.9 (203) 15.9 (141) 5.03 (1.455)
Note: SDA=Strongly Disagree; DA=Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; A=Agree;
SA=Strongly Agree.
Values Represent: %(n)
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Table A.4
Item-wise Analysis for Personal Utility Items at 2-3 Week Follow-up Survey
Item
Group
SDA
SWDA
N
SWA
SA
Mean (SD)
The information I received from [company] has influenced how I will manage my health in the future.
19-39 years old (350)
4.3 (15)
6.6 (23)
15.4 (54) 55.7 (195) 18 .0 (63)
3.77 (.965)
40-59 years old (315)
4.1 (13)
5.7 (18)
18.1 (57) 50.8 (160)
21.3 (67)
3.79 (.977)
60+ years old (223)
6.7 (15)
7.2 (16)
24.2 (54)
43.0 (96)
18.8 (42) 3.60 (1.081)
Overall (888)
4.8 (43)
6.4 (57) 18.6 (165) 50.8 (451) 19.4 (172) 3.73 (1.001)
Having personal genomic testing made me feel like I have more control over my health.
19-39 years old (350)
2.3 (8)
4.6 (16)
15.7 (55) 47.7 (167) 29.7 (104)
3.98 (.919)
40-59 years old (315)
4.8 (15)
4.8 (15)
16.8 (53) 46.3 (146)
27.3 (86) 3.87 (1.023)
60+ years old (223)
8.1 (18)
8.1 (18)
18.8 (42)
38.1 (85)
26.9 (60) 3.68 (1.187)
Overall (888)
4.6 (41)
5.5 (49) 16.9 (150) 44.8 (398) 28.2 (250) 3.86 (1.034)
Having personal genomic testing helped me to get a better perspective on my health status.
19-39 years old (350)
1.7 (6)
3.4 (12)
10.3 (36) 49.4 (173) 35.1 (123) 4.13 (0.855)
40-59 years old (315)
3.2 (10)
2.5 (8)
9.5 (30) 50.2 (158) 34.6 (109) 4.10 (0.906)
60+ years old (223)
4.5 (10)
4.5 (10)
11.7 (26) 46.2 (103)
33.2 (74) 3.99 (1.151)
Overall (888)
2.9 (26)
3.4 (30)
10.4 (92) 48.9 (434) 34.5 (306) 4.09 (1.089)
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.
Values represent %(n).
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Table A.5
Item-wise Analysis for Personal Utility Items at 6 Month Follow-up Survey
Item
Group
SDA
SWDA
N
SWA
SA
Mean (SD)
The information I received from [company] has influenced how I will manage my health in the future.
19-39 years old (350)
6.3 (22)
8.9 (31)
23.7 (83)
45.7 (160)
15.4 (54) 3.55 (1.055)
40-59 years old (315)
6.3 (20)
7.0 (22)
25.1 (79)
42.2 (133)
19.4 (61)
3.61 (1.72)
60+ years old (223)
11.2 (25)
7.6 (17)
26.5 (59)
41.7 (93)
13.0 (29) 3.38 (1.151)
Overall (888)
7.5 (67)
7.9 (70) 24.9 (221)
43.5 (386) 16.2 (144) 3.53 (1.089)
Having personal genomic testing made me feel like I have more control over my health.
19-39 years old (350)
4.9 (17)
9.4 (33)
18.6 (65)
48.6 (170)
18.6 (65) 3.67 (1.038)
40-59 years old (315)
6.7 (21)
6.0 (19)
19.o (60 )
44.8 (141)
23.5 (74) 3.72 (1.093)
60+ years old (223)
9.9 (22)
6.3 (14)
22.0 (49)
40.8 (91)
21.1 (47) 3.57 (1.179)
Overall (888)
6.8 (60)
7.4 (66) 19.6 (174)
45.3 (402) 20.9 (186) 3.66 (1.095)
Having personal genomic testing helped me to get a better perspective on my health status.
19-39 years old (350)
3.1 (11)
6.6 (23)
14.9 (52)
52.0 (182)
23.4 (82)
3.86 (.955)
40-59 years old (315)
3.8 (12)
4.8 (15)
12.8 (40)
48.9 (154)
29.8 (94)
3.96 (.980)
60+ years old (223)
7.2 (16)
4.5 (10 )
16.6 (37)
43.9 (98)
27.8 (62)
3.81 (1.112)
Overall (888)
4.4 (39)
5.4 (48) 14.5 (129)
48.9 (434) 26.8 (238)
3.88 (1.006)
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.
Values represent %(n).

Table A.6
Response Efficacy Item at Baseline and 6 Month Follow-up Surveys
Group
SDA
SWDA
N
SWA
A
Mean (SD)
What I learned from my personal genomic testing can help reduce my chances of getting sick.
19-39 years old (350)
3.1 (11)
15.3 (54) 20.9 (73) 50.6 (177) 10.0 (35)
3.49 (.975)
40-59 years old (315)
3.8 (12)
13.0 (41) 29.8 (94) 43.2 (136) 10.2 (32)
3.43 (.970)
Baseline
60+ years old (223)
4.5 (10)
9.9 (22) 39.5 (88) 36.8 (82)
9.4 (21)
3.37 (.944)
Overall (888)
3.7 (33) 13.2 (117) 28.7 (255) 44.5 (395)
9.9 (88)
3.44 (.965)
19-39 years old (350)
6.9 (24) 16.9 (59) 30.6 (107) 37.4 (131)
8.3 (29) 3.23 (1.047)
40-59 years old (315)
6.7 (21) 11.7 (37) 29.8 (94) 36.2 (114) 15.6 (49) 3.42 (1.093)
6 Month Follow-up
60+ years old (223)
11.7 (26) 10.3 (23) 32.7 (73) 35.4 (79)
9.9 (22) 3.22 (1.130)
Overall (888)
8.0 (71) 13.4 (119) 30.9 (274) 36.5 (324) 11.3 (100) 3.30 (1.088)
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.
Values represent %(n).
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Table A.7
Item-wise Analysis of Importance of Reasons to Test
Group
NI
SWI
VI
Mean (SD)
Curiosity about my genetic make up
19-39 years old
1.7 (6)
20.6 (72) 77.7 (272) 2.76 (.466)
40-59 years old
1.6 (5)
21.0 (66) 77.5 (244) 2.76 (.464)
60+ years old
0.4 (1)
17.0 (38) 82.5 (184) 2.82 (.396)
Overall
1.4 (12) 19.8 (176) 78.8 (700) 2.77 (.449)
Interest in finding out about my personal risk for specific diseases
19-39 years old
4.6 (16)
23.1 (81) 72.3 (253) 2.68 (.558)
40-59 years old
7.0 (22)
29.9 (94) 63.1 (198) 2.56 (.623)
60+ years old
11.2 (25)
38.6 (86) 50.2 (112) 2.39 (.681)
Overall
7.1 (63) 29.4 (261) 63.5 (563) 2.56 (.623)
Desire to learn about my genetic makeup without going through a physician
19-39 years old 34.6 (121) 34.0 (119) 31.4 (110) 1.97 (.813)
40-59 years old 38.7 (122)
30.2 (95)
32.2 (98) 1.92 (.834)
60+ years old
51.6 (115)
28.7 (64)
19.7 (44) 1.68 (.784)
Overall
40.3 (358) 31.3 (278) 28.4 (252) 1.88 (.821)
Desire to improve my health
19-39 years old
11.4 (4) 41.4 (145) 47.1 (165) 2.36 (.678)
40-59 years old
10.8 (34) 37.9 (119) 51.3 (161) 2.40 (.677)
60+ years old
18.8 (42)
38.1 (85)
43.0 (96) 2.24 (.750)
Overall
13.1 (116) 39.3 (349) 47.6 (422) 2.34 (.699)
Interest in finding out about my individual response to different types of medications
19-39 years old
18.3 (64) 39.7 (139) 42.0 (147) 2.24 (.740)
40-59 years old
22.3 (70) 34.7 (109) 43.0 (135) 2.21 (.782)
60+ years old
24.2 (54)
35.0 (78)
40.8 (91) 2.17 (.791)
Overall
21.2 (188) 36.8 (326) 42.1 (373) 2.21 (.768)
Desire to create a better plan for the future
19-39 years old
12.9 (45) 38.3 (134) 48.9 (171) 2.36 (.699)
40-59 years old
17.8 (56) 34.1 (107) 48.1 (151) 2.30 (.755)
60+ years old
26.5 (59)
31.4 (70)
42.2 (94) 2.16 (.815)
Overall
18.0 (160) 35.1 (311) 46.9 (416) 2.29 (.753)
Personal interest in genetics in general
19-39 years old
6.9 (24) 36.6 (127) 56.9 (199) 2.50 (.623)
40-59 years old
5.7 (18) 39.4 (124) 54.9 (173) 2.49 (.604)
60+ years old
8.1 (18)
35.4 (79) 56.5 (126) 2.48 (.643)
Overall
6.8 (60) 37.2 (330) 56.1 (498) 2.49 (.621)
The service seemed like it would be fun and entertaining
19-39 years old
16.6 (58) 40.6 (142) 42.9 (150) 2.26 (.726)
40-59 years old
25.8 (81) 42.7 (134)
31.5 (99) 2.06 (.756)
60+ years old
25.1 (56)
43.0 (96)
31.8 (71) 2.07 (.753)
Overall
22.0 (195) 41.9 (372) 36.1 (320) 2.14 (.749)
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Table A.7 continued
Item-wise Analysis of Importance of Reasons to Test
Group
NI
SWI
VI
Mean (SD)
Other members of my family are using personal genomic services
19-39 years old 80.0 (132)
11.4 (40)
8.6 (30) 1.29 (0.614)
40-59 years old 82.9 (261)
10.2 (32)
7.0 (22) 1.24 (0.569)
60+ years old
70.8 (158)
14.8 (33)
14.3 (32) 1.44 (0.732)
Overall
78.4 (699) 11.8 (105)
9.5 (84) 1.31 (0.634)
Desire to learn more about my genetics because I have limited information about my
family health history
19-39 years old 30.3 (106) 32.6 (114)
37.1 (130) 2.07 (0.819)
40-59 years old 32.7 (103) 35.2 (111)
32.1 (101) 1.99 (0.806)
60+ years old
23.8 (53)
38.6 (86)
37.7 (84) 2.14 (0.773)
Overall
29.5 (262) 35.0 (311)
35.5 (315) 2.06 (0.804)
Desire to learn more about my genetics because I am adopted
19-39 years old 93.7 (328)
0.6 (2)
5.7 (20) 1.12 (0.470)
40-59 years old 91.1 (287)
2.5 (8)
6.3 (20) 1.15 (0.507)
60+ years old
96.4 (215)
0.9 ( 2)
2.7 (6) 1.06 (0.336)
Overall
93.5 (830)
1.4 (12)
5.2 (46) 1.12 (0.455)
Interest in getting information about the risk of health conditions for my current
children or future children.
19-39 years old
21.4 (75)
27.4 (96)
51.1 (179) 2.30 (0.800)
40-59 years old 42.9 (135)
21.0 (66)
36.2 (114) 1.93 (0.888)
60+ years old
30.5 (68)
26.9 (60)
42.6 (95) 2.21 (0.848)
Overall
31.3 (278) 25.0 (222)
43.7 (388) 2.12 (0.858)
Note: NI=Not Important, SWI=Somewhat Important, VI=Very Important.
Values represent %(n).
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Table A.8
Item-wise Analysis of Consideration Given to Reasons to Test
Group
DNC
CSW
CAL
Mean (SD)
How well the results predict whether or not I’m going to get a particular disease
19-39 years old
15.1 (53) 51.7 (181) 33.1 (116)
2.18 (.672)
40-59 years old
14.0 (44) 55.2 (174)
30.8 (97)
2.17 (.649)
60+ years old
24.2 (54) 46.6 (104)
29.1 (65)
2.05 (.730)
Overall
17.0 (151) 51.7 (459) 31.3 (278)
2.14 (.681)
Privacy of my genetic information
19-39 years old
19.4 (68) 41.7 (146) 38.9 (136)
2.19 (.739)
40-59 years old
15.9 (50) 38.7 (122) 45.4 (143)
2.30 (.726)
60+ years old
27.4 (61)
35.0 (78)
37.7 (84)
2.10 (.802)
Overall
20.2 (179) 39.0 (346) 40.9 (363)
2.21 (.754)
Whether or not there are health-related actions I can take as a result of learning my
genetic information
19-39 years old
9.1 (32) 38.0 (133) 52.9 (185)
2.44 (.656)
40-59 years old
7.9 (25) 35.9 (113) 56.2 (177)
2.48 (.640)
60+ years old
11.7 (26)
39.9 (89) 48.4 (108)
2.37 (.684)
Overall
9.3 (83) 37.7 (335) 52.9 (470)
2.44 (.658)
The possibility that I might receive unwanted information
19-39 years old 29.1 (102) 41.4 (145) 29.4 (103)
2.00 (.766)
40-59 years old 33.3 (105) 44.1 (139)
22.5 (71)
1.89 (.741)
60+ years old
49.8 (111)
37.7 (84)
12.6 (28)
1.63 (.698)
Overall
35.8 (318) 41.4 (368) 22.7 (202)
1.87 (.754)
Cost of services
19-39 years old
19.4 (68) 41.7 (146) 38.9 (136)
2.19 (.739)
40-59 years old
21.0 (66) 47.0 (148) 32.1 (101)
2.11 (.721)
60+ years old
35.9 (80) 45.3 (101)
18.8 (42)
1.83 (.721)
Overall
24.1 (214) 44.5 (395) 31.4 (279)
2.07 (.742)
The education materials made available through the company
19-39 years old 33.4 (117) 46.0 (161)
20.6 (72)
1.87 (.725)
40-59 years old
27.0 (85) 50.8 (160)
22.2 (70)
1.95 (.701)
60+ years old
26.5 (59) 47.1 (105)
26.4 (59)
2.00 (.729)
Overall
29.4 (261) 48.0 (426) 22.6 (201)
1.93 (.719)
The convenience of being tested at home
19-39 years old
18.9 (66) 37.1 (130) 44.0 (154)
2.25 (.753)
40-59 years old
16.8 (53) 40.6 (128) 42.5 (134)
2.26 (.727)
60+ years old
14.3 (32)
35.9 (80) 49.8 (111)
2.35 (.720)
Overall
17.0 (151) 38.1 (338) 44.9 (399)
2.28 (.736)
Note: DNC=Did not consider; CSW=Considered Somewhat; CAL=Considered a lot.
Values Represent % (n).
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Table A.9
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing
Results
Group
Never
Rarely
Sometimes
Often
Mean (SD)
Felt upset about my results
19-39 years old
71.7 (251) 21.7 (76)
6.0 (21)
0.6 (2)
1.35 (0.62)
40-59 years old
73.7 (232) 20.3 (64)
5.7 (18)
0.3 (1)
1.33 (0.60)
60+ years old
74.0 (165) 17.5 (39)
4.9 (11)
3.6 (8)
1.38 (0.74)
Overall
73.0 (648) 20.2 (179)
50 (5.6)
1.2 (11)
1.35 (0.64)
Felt relieved about my resultsa
19-39 years old
15.4 (54) 17.1 (60) 47.4 (166)
20.0 (70)
2.72 (0.96)
40-59 years old
21.3 (67) 19.7 (62) 44.1 (139)
14.9 (47)
2.53 (0.99)
60+ years old
19.3 (43) 16.6 (37)
38.6 (86)
25.6 (57)
2.70 (1.05)
Overall
18.5 (164) 17.9 (159) 44.0 (391) 19.6 (174)
2.65 (1.00)
a
Felt happy about my results
19-39 years old
12.3 (43) 19.1 (67) 44.6 (156)
24.0 (84)
2.80 (0.94)
40-59 years old
15.2 (48) 20.3 (64) 46.7 (147)
17.8 (56)
2.67 (0.94)
60+ years old
12.1 (27) 14.8 (33) 45.7 (102)
27.4 (61)
2.88 (0.95)
Overall
13.3 (118) 18.5 (164) 45.6 (405) 22.6 (201)
2.78 (0.95)
Felt motivated to change my lifestyle because of my results
19-39 years old
29.4 (103) 31.4 (110) 30.0 (105)
9.1 (32)
2.19 (0.96)
40-59 years old
23.8 (75) 27.6 (87) 34.9 (110)
13.7 (43)
2.38 (0.99)
60+ years old
26.5 (59) 30.9 (69)
34.1 (76)
8.5 (19)
2.25 (0.94)
Overall
26.7 (237) 30.0 (266) 32.8 (291)
10.6 (94)
2.27 (0.97)
Worried about my risk of getting diseases
19-39 years old
36.9 (129) 44.0 (154)
18.0 (63)
1.1 (4)
1.83 (0.75)
40-59 years old
38.7 (122) 41.9 (132)
15.9 (50)
3.5 (11)
1.84 (0.81)
60+ years old
44.4 (99) 35.0 (78)
19.7 (44)
0.9 (2)
1.77 (0.79)
Overall
39.4 (350) 41.0 (364) 17.7 (157)
1.9 (17)
1.82 (0.79)
Table Continues
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Table A.9 continued
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing
Results
Group
Never
Rarely
Sometimes Often
Mean (SD)
Been uncertain about what my results mean about my risk of developing diseases
19-39 years old
46.3 (162) 32.3 (113)
19.7 (69)
1.7 (6)
1.77 (0.82)
40-59 years old
47.3 (149) 33.7 (106)
16.2 (51)
2.9 (9)
1.75 (0.83)
60+ years old
93 (41.7) 35.0 (78)
17.5 (39)
5.8 (13)
1.87 (0.90)
Overall
45.5 (404) 33.4 (297) 17.9 (159)
3.2 (28)
1.79 (0.85)
Been uncertain about what my results mean for my child(ren)’s and/or family’s disease risk
19-39 years old
50.3 (176) 28.9 (101)
18.6 (65)
2.3 (8)
1.73 (0.84)
40-59 years old
55.9 (176) 26.3 (83)
14.6 (46)
3.2 (10)
1.65 (0.84)
60+ years old
47.1 (105) 27.4 (61)
21.5 (48)
4.0 (9)
1.83 (0.91)
Overall
51.5 (457) 27.6 (245) 17.9 (159)
3.0 (27)
1.73 (0.86)
Felt unsure about what to do to prevent diseases
19-39 years old
55.1 (193) 31.1 (109)
11.4 (40)
2.3 (8)
1.61 (0.78)
40-59 years old
55.6 (175) 28.9 (91)
13.0 (41)
2.5 (8)
1.63 (0.81)
60+ years old
49.3 (110) 35.0 (78)
13.9 (31)
1.8 (4)
1.68 (0.78)
Overall
53.8 (478) 31.3 (278) 12.6 (112)
2.3 (20)
1.63 (0.79)
Felt concerned about how my results will affect my insurance status
19-39 years old
73.4 (257) 15.7 (55)
9.7 (34)
1.1 (4)
1.39 (0.71)
40-59 years old
64.0 (201) 24.5 (77)
8.9 (28)
2.5 (8)
1.50 (0.76)
60+ years old
76.7 (171) 14.8 (33)
7.6 (17)
0.9 (2)
1.33 (0.66)
Overall
70.9 (629) 18.6 (165)
8.9 (79)
1.6 (14)
1.41 (0.72)
Had difficulty talking about my results with others
19-39 years old
81.7 (286) 14.3 (50)
4.0 (14)
0.0 (0)
1.22 (0.50)
40-59 years old
72.4 (228) 21.6 (68)
3.8 (12)
2.2 (7)
1.36 (0.66)
60+ years old
77.1 (172) 14.3 (32)
5.4 (12)
3.1 (7)
1.35 (0.72)
Overall
77.3 (686) 16.9 (150)
4.3 (38)
1.6 (14)
1.30 (0.63)
Table Continues

Table A.9 continued
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing
Results
Group
Never
Rarely
Sometimes Often
Mean (SD)
Wanted to tell others about my resultsa
19-39 years old
12.0 (42)
18.6 (65) 46.3 (162)
23.1 (81)
2.81 (0.93)
40-59 years old
13.0 (41)
19.0 (60) 47.0 (148)
21.0 (66)
2.76 (0.93)
60+ years old
17.9 (40)
18.4 (41) 46.6 (104)
17.0 (38)
2.63 (0.97)
Overall
13.9 (123) 18.7 (166) 46.6 (414) 20.8 (185)
2.74 (0.94)
Note: Values represent % (n)
a
These results were reverse coded for use in calculation of Perceived Severity Scale
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Table A.10
Perceived Vulnerability Item-wise Analysis Measuring Perceptions of Personal Risk for Developing Health Conditions
Groups
MLTA
LTA
A
HTA
MHTA Already Dx Mean (SD)
Alzheimer’s
19-39 years old
8.9 (31) 34.3 (120) 38.9 (136)
14.3 (50) 3.7 (13)
0.0 (0) 2.70 (0.95)
Disease
40-59 years old
9.2 (29) 34.1 (107) 34.1 (107)
16.9 (53) 5.7 (18)
0.0 (0) 2.76 (1.03)
60+ years old
17.5 (39)
31.8 (71)
29.6 (66)
17.5 (39)
3.6 (8)
0.0 (0) 2.58 (1.08)
Overall
11.2 (99) 33.6 (298) 34.8 (309) 16.0 (142) 4.4 (39)
0.0 (0) 2.69 (1.01)
Breast
19-39 years old
6.0 (12)
25.1 (50) 51.3 (102)
14.6 (29)
2.5 (5)
0.5 (1) 2.85 (0.95)
a
Cancer
40-59 years old
8.9 (18)
30.7 (62)
46.0 (93)
11.9 (24)
0.5 (1)
2.0 (4) 2.76 (1.21)
60+ years old
12.8 (16)
27.2 (34)
41.6 (52)
12.8 (16)
2.4 (3)
3.2 (4) 2.84 (1.47)
Overall
8.7 (46) 27.8 (146) 47.0 (247)
13.1 (69)
1.7 (9)
1.7 (9) 2.82 (1.19)
Prostate
19-39 years old
9.3 (14)
17.2 (26)
53.6 (81)
13.2 (20) 6.6 (10)
0.0 (0) 2.91 (0.97)
Cancera
40-59 years old
3.6 (4)
22.3 (25)
58.0 (65)
13.4 (15)
0.9 (1)
1.8 (2) 2.96 (1.09)
60+ years old
7.1 (7)
17.3 (17)
42.9 (42)
15.3 (15)
4.1 (4)
13.3 (13) 3.71 (2.26)
Overall
6.9 (25)
18.8 (68) 52.1 (188)
13.9 (50) 4.2 (15)
4.2 (15) 3.14 (1.50)
Colorectal
19-39 years old
8.3 (29)
19.7 (69) 55.1 (193)
14.6 (51)
2.0 (7)
0.3 (1) 2.84 (0.91)
Cancer
40-59 years old
6.7 (21)
21.3 (67) 52.9 (166)
17.5 (55)
1.6 (5)
0.0 (0) 2.86 (0.84)
60+ years old
7.2 (16)
34.1 (76)
40.8 (91)
14.3 (32)
3.6 (8)
0.0 (0) 2.73 (0.92)
Overall
7.4 (66) 23.9 (212) 50.7 (450) 15.6 (138) 2.3 (20)
0.1 (1) 2.82 (0.89)
Lung Cancer 19-39 years old
13.1 (46)
24.6 (86) 49.1 (172)
10.9 (38)
2.3 (8)
0.0 (0) 2.65 (0.92)
40-59 years old
15.0 (47)
28.7 (90) 44.6 (140)
10.5 (33)
1.0 (3)
0.3 (1) 2.56 (0.98)
60+ years old
24.7 (55)
30.5 (68)
30.0 (67)
13.0 (29)
0.9 (2)
0.9 (2) 2.40 (1.20)
Overall
16.7 (148) 27.5 (244) 42.7 (379) 11.3 (100) 1.5 (13)
0.3 (3) 2.55 (1.02)
Diabetes
19-39 years old
9.7 (34) 20.6 (72 ) 45.1 (158)
18.6 (65) 5.1 (18)
0.9 (3) 2.94 (1.14)
40-59 years old
8.6 (27)
24.5 (77) 38.2 (120)
22.3 (70) 4.5 (14)
1.9 (6) 3.01 (1.30)
60+ years old
13.5 (30)
25.1 (56)
34.4 (77)
14.8 (33) 4.5 (10)
7.6 (17) 3.17 (1.96)
Overall
10.3 (91) 23.1 (205) 40.0 (355) 18.9 (168) 4.7 (42)
2.9 (26) 3.02 (1.44)
Table Continues
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Table A.10 continued
Perceived Vulnerability Item-wise Analysis Measuring Perceptions of Personal Risk for Developing Health Conditions
Groups
MLTA
LTA
A
HTA
MHTA Already Dx Mean (SD)
Heart
19-39 years old
7.4 (26) 18.6 (65) 40.6 (142)
26.6 (93)
6.6 (23)
0.3 (1) 3.08 (1.05)
Disease
40-59 years old
3.8 (12) 14.6 (46) 42.4 (133) 33.1 (104)
5.7 (18)
0.3 (1) 3.24 (0.96)
60+ years old
5.4 (12) 22.4 (50)
35.4 (79)
24.2 (54)
5.4 (12)
7.2 (16) 3.45 (1.82)
Overall
5.6 (50) 18.2 (161) 39.9 (354) 28.3 (251)
6.0 (53)
2.0 (18) 3.23 (1.27)
Obesity
19-39 years old
15.7 (55) 21.4 (75) 38.9 (136)
16.3 (57)
2.6 (9)
5.1 (18) 2.99 (1.72)
40-59 years old
10.5 (33) 14.6 (46) 36.9 (116)
22.6 (71)
3.2 (10)
12.1 (38) 3.66 (2.20)
60+ years old
17.0 (38) 17.9 (40)
30.5 (68)
21.5 (48)
3.6 (8)
9.4 (21) 3.33 (2.13)
Overall
14.2 (126) 18.2 (161) 36.1 (320) 19.8 (176)
3.0 (27)
8.7 (77) 3.31 (2.03)
Parkinson’s
19-39 years old
11.7 (41) 27.1 (95) 51.1 (179)
9.7 (34)
0.3 (1)
0.0 (0) 2.60 (0.83)
Disease
40-59 years old
10.8 (34) 32.2 (101) 46.2 (145)
7.3 (23)
2.5 (8)
1.0 (3) 2.64 (1.07)
60+ years old
16.6 (37) 39.0 (87)
32.7 (73)
7.2 (16)
1.8 (4)
2.7 (6) 2.55 (1.40)
Overall
12.6 (112) 31.9 (283) 44.8 (397)
8.2 (73)
1.5 (13)
1.0 (9) 2.60 (1.08)
Note: MLTA=Much Lower Than Average; LTA= Lower Than Average; A=Average; HTA= Higher Than Average;
MHTA=Much Higher Than Average. Values represent % (n).
a
This item asked based on participant’s reported sex.
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Table A.11
Complete Demographics of the Participant Sample Used for Dissertation Analyses
Gender
Group
Male
Female
19-39 years old
43.1 (151)
56.9 (199)
40-59 years old
35.9 (113)
64.1 (202)
60+ years old
42.9 (98)
56.1 (125)
Overall
40.8 (362)
59.2 (526)
Adopted
Group
Yes
No
19-39 years old
6.0 (21)
94 (329)
40-59 years old
7.9 (25)
92.1 (290)
60+ years old
2.2 (5)
97.8 (218)
Overall
5.7 (51)
94.3 (837)
Relationship
Group
Single
Married
Widowed
Divorced/Sep
Partnered/LTR
Status
19-39 years old
36.3 (127)
34.6 (121)
0.0 (0)
5.1 (18)
24.0 (84)
40-59 years old
14.6 (46)
61.0 (192)
1.6 (5)
12.4 (39)
10.5 (33)
60+ years old
5.4 (12)
66.8 (149)
6.3 (14)
12.6 (28)
9.0 (20)
Overall
20.8 (185)
52.0 (462)
2.1 (19)
9.6 (85)
15.4 (137)
Biological
Group
Yes
No
Children
19-39 years old
18.9 (66)
81.1 (284)
40-59 years old
60.6 (191)
39.4 (124)
60+ years old
78.5 (175)
21.5 (48)
Overall
48.6 (432)
51.4 (456)
Number of
Group
1
2
3
4
5
6
7+
Biological
19-39 years old
51.5 (34)
42.4 (28)
4.5 (3)
1.5 (1)
0.0 (0)
0.0 (0)
0.0 (0)
Children
40-59 years old
25.7 (49)
45.5 (87)
21.5 (41) 5.2 (10)
2.1 (4)
0.0 (0)
0.0 (0)
60+ years old
17.7 (31)
48.6 (85)
25.7 (45)
2.3 (4)
4.0 (7)
1.1 (2)
0.6 (1)
Overall
26.4 (114)
46.3 (200)
20.6 (89) 3.5 (15) 2.5 (11)
0.5 (2)
0.2 (1)
Table Continues
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Table A.11 continued
Complete Demographics of the Participant Sample Used for Dissertation Analyses
Are any
Group
Yes
No
Biological
19-39 years old
95.5 (63)
4.5 (3)
Children
40-59 years old
44.0 (84)
56.0 (107)
under 18?
60+ years old
0.6 (1)
99.4 (174)
Overall
34.3 (148)
65.7 (284)
Hispanic/
Group
Yes
No
Latino
19-39 years old
6.9 (24)
93.1 (3.26)
40-59 years old
5.1 (16)
94.9 (299)
60+ years old
1.3 (3)
98.7 (220)
Overall
4.8 (43)
95.2 (845)
Race
Am Indian
Black or
Hawaiian or
Group
/Native
Asian
African
Pacific
White
Other
Alaskan
American
Islander
19-39 years old
3.1 (11)
9.7 (34)
3.7 (13)
1.4 (5)
86.6 (303)
7.4 (26)
40-59 years old
1.9 (6)
2.2 (7)
3.8 (12)
0.3 (1)
92.4 (291)
4.8 (15)
60+ years old
3.6 (8)
0.0 (0)
1.3 (3)
0.4 (1)
95.5 (213)
3.1 (7)
Overall
2.8 (25)
4.6 (41)
3.2 (28)
0.8 (7)
90.9 (807)
5.4 (48)
Household
$40,000$70,000$100,000$200,000Group
<$40,000
>$500,000
Income
$69,999
$99,999
$199,000
$500,000
Past 12
19-39 years old
24.6 (93)
16.3 (57)
18.0 (63)
29.1 (102)
8.3 (29)
1.7 (6)
months
40-59 years old
11.8 (36)
16.0 (49)
20.6 (63)
36.3 (111)
12.4 (38)
2.9 (9)
60+ years old
12.7 (28)
23.1 (51)
22.6 (50)
28.1 (62)
12.2 (27)
1.4 (3)
Overall
17.9 (157)
17.9 (157)
20.1 (176)
31.4 (275)
10.7 (94)
2.1 (18)
Table Continues
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Table A.11 continued
Complete Demographics of the Participant Sample Used for Dissertation Analyses
Highest Group
Some
Some
Grade
HS/
Some
College
Master’s
Level
Grad
Doc.
Sch.
GED
College
Degree
Degree
of Ed.
Sch.
Work
19-39
years 0.3 (1) 2.9 (10) 14.0 (49) 37.1 (130) 12.0 (42)
18.0 (63) 5.1 (18)
old
40-59
years 0.0 (0) 2.9 (9) 17.8 (56)
31.1 (98) 11.7 (37)
20.3 (64)
2.2 (7)
old
60+
years 0.9 (2) 4.0 (9) 20.2 (45)
17.9 (40) 11.7 (26)
24.7 (55)
3.6 (8)
old
Overall 0.3 (3) 3.2 (28) 16.9 (150) 30.2 (268) 11.8 (105) 20.5 (182) 3.7 (33)
Current Group
SelfEmploy
Full Time
Part-time
Retired
Unemployed
employed
ment
Status
19-39
62.9 (220)
12.6 (44)
0.6 (2)
5.7 (20)
8.0 (28)
years
old
40-59
58.7 (185)
6.7 (21)
11.1 (35)
13.0 (41)
7.3 (23)
years
old
60+
22.4 (50)
9.0 (20) 63.2 (141)
7.6 (17)
2.7 (6)
years
old
Overall
51.2 (455)
9.6 (85) 20.0 (178)
8.8 (78)
6.4 (57)
Note: Values represent % (n).

PhD,
DSc,
EdD

Doc. Equiv.

6.0 (21)

4.5 (16)

6.7 (21)

7.3 (23)

8.5 (19)

8.5 (19)

6.9 (61)

6.6 (58)
Not
Student
working
by choice
20.3 (71)
4.6 (16)

1.6 (5)

9.2 (29)

0.0 (0)

3.6 (8)

8.6 (76)

6.0 (53)

APPENDIX B
DATA DISTRIBUTION AGREEMENT WITH IMPACT OF PERSONAL GENOMICS
STUDY GROUP
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